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ORGAN SPECIFIC VASCULAR RESPONSE TO ANGIOPOIETIN 2 AFFECTS
BREAST CANCER METASTATIC ORGANOTROPISM

Eliot Sananikone Fletcher, MPH, Ph.D.*
Advisory Professor: Raghu Kalluri, MD, Ph.D.

The solid tumor microenvironment, pre-metastatic niche, and fibrotic
environment are known to have significant biochemical and biomechanical
similarities to the fibrotic environment. All have significantly increased levels of
factors such as TGFβ, HIF1α, TNFα, PDGF, VEGF, FGF, interleukins and other
growth factors that are known to be pro-tumorigenic. Clinical and basic science
research has shown that fibrosis presents an environment that favors tumor
growth, such as hepatocellular carcinoma being commonly preceded by liver
cirrhosis, or bleomycin induced lung fibrosis enhancing pulmonary metastasis in
mouse models of breast cancer. In addition to the evidence indicating that fibrosis
enhances primary tumor growth and metastasis it is also well characterized that
primary tumor metastasis has specific organotropism, for example breast cancer
commonly spreads to the lungs, brain, bone, liver and lymph nodes. However,
whether non-organtropic fibrosis can redirect metastasis to the damaged organ
has not been investigated.

To elucidate the fibrotic effect on tumor organotropism we induced fibrosis
in the organotropic lungs and in the non-organotropic kidney of two mouse models
of breast cancer, the 4T1 murine cancer cell line model and the genetic MMTVPymt model, both of which are known to metastasize. Using histopathology,
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microarrays, gene expression by polymerase chain reaction, ELISA, chemokine
array, and in vitro experiments we demonstrate that despite the pro-tumorigenic
environment, kidney fibrosis does not redirect metastasis to the non -organotropic
damaged organ. However, mice with kidney fibrosis had increased metastasis to
their lungs. Furthermore, we found that kidney fibrosis increas es the circulating
levels of the pro-angiogenic factor Angiopoietin 2 that increased vascular
permeability of the lungs, but not the kidneys. In fact, while fibrotic lungs showed
decreased expression of endothelial tight gap junction protein Claudin -5, the
fibrotic kidneys had an elevated expression of Claudin-5.

Our findings suggest that despite the similarities between fibrosis, the
tumor microenvironment and the pre-metastatic niche, that while it can enhance
tropic metastatic disease, it cannot redirect organotropism indicating that other
factors must be involved in directing organotropism. Here we report t hat tumor
organotropism may be a result of organ specific vascular responses to excess
circulating factors and increased fibrotic factors . These findings indicate that
organotropism is directly related to and as a result of organ specific vascular
alterations.
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Chapter 1
Background and Significance

2

Metastatic disease

Metastatic disease is the leading cause of mortality in patients diagnosed with
cancer (Patrick Mehlen and Alain Puisieux 2006, Li and King 2012). It is estimated that
metastatic disease is responsible for 90% of human cancer deaths (Li and King 2012). In
2016 1,685,210 people were diagnosed with cancer in the United States alone, 595,690
died from that diagnosis (National Institute of Health). Therefore 536,121 people died due to
metastatic disease in the United States in 2016. Globally, 7.38 million people died from
metastatic disease in 2012 (World Health Organization). Although metastatic disease
occurs in almost all cancer types including the hematological cancers, breast cancer
metastasis is one of the more readily researched and characterized pathologies. According
to the National Cancer Institute there are 246,660 new cases of female and male breast
cancer a year and 40,450 deaths (National Institute of Health). With modern preventative
measures such as early mammography it is possible to detect primary breast tumors before
they become malignant. Early detection measures with breast cancer allow for the surgical
removal of breast cancer tissue either by resection or in more advanced cases mastectomy.
While resection and mastectomy have scarification outcomes, these can be fixed by plastic
surgery and loss of breast tissue does not place life threatening burden on the patient.
However, if breast cancer cells metastasize to organs required for the sustainment of the
organism this can impose a life threatening diagnosis, meaning that 100% of breast cancer
deaths are due to metastasis. Thus the early detection of breast cancer since the late 1990s
has significantly reduced the numbers of breast cancer related mortalities. However,
metastasis from breast cancer and other cancer diagnosis remains the primary cause of
cancer patient mortality (Bleyer and Welch 2013).
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The process of metastasis follows a defined route based around fundamental
anatomy and the location of the primary tumor (Figure 1) (Fidler 2003). Based on
Kundson’s Two hit hypothesis (Knudson 2000), two genetic mutations are required to occur
in a cell that prompts the uncontrolled proliferation of that cell. The loss of a tumor
suppressor and the gain of an oncogene are deemed sufficient to begin neoplastic
formation. Initial formation of hyperplastic tissue begins the process of further genomic
mutation which in turn begets even more genetic mutations (genomic instability), leading to
dysplasia and cancer in situ (Gordon 2010). The increase in mutations acts as a Darwinian
survival mechanism allowing the strongest tumor cells to survive and uncontrollably
propagate (Pepper and Maley 2009). Most commonly this occurs in epithelial tissue which is
separated from the surrounding stroma and vasculature by a basement membrane.
Approximately 80-90% of tumors are epithelial in origin, the hematologic cancers make up
8%, and cancer of the connective tissue is around 1-2% of cancer diagnosis (National
Cancer Institute). All three types of cancer are known to undergo metastasis. As the tumor
continues to progress it can begin to invade through the basement membrane by secreting
matrix metalloproteinases that can degrade extracellular matrix proteins (Peinado and
Lyden 2011). Once the basement membrane has been breached cells from the primary
tumor may cross the endothelial cell wall into the circulation via paracellular transendothelial
migration, also known as intravasation (Junqueira and Avraham 2011).
In addition to degrading basement membrane via the secretion of matrix
metalloproteinases, tumors also secrete significant angiogenic factors such as vascular
endothelial growth factor (VEGF), angiopoietins, transforming growth factor β (TGFβ), tumor
necrosis factor α (TNFα), epidermal growth factor (EGF) and many others (Nishida and
Kojiro 2006). This continued secretion of proangiogenic factors induces the growth of new
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vasculature within and around the tumor. However, unlike healthy organ vasculature, tumor
vasculature is dysregulated and malformed often leading to leaky vessels, poor perfusion,
and diminished immune cell trafficking (Siemann 2011, Keskin and Kalluri 2013). Tumor
vascular dysregulation increases the hypoxic environment of the tumor and perpetuates the
survival of tumor cells that will be more likely to survive in austere conditions such as the
circulatory system. It also presents a route for tumor cells to more easily enter the
circulation and travel to distant organ sites (Siemann 2011).
Once tumor cells enter the circulation they are known as circulating tumor cells.
Within the circulation these cells have to survive stresses that epithelial cells are not
typically exposed to such as high shear stress from blood flow (Joosse and Pantel 2014).
The malignant epithelial cells have to undergo a number of changes prior to entering the
circulation that increases their capacity to survive. For example, healthy epithelial cells
require attachments to adjacent cells via tight gap junctions, adherent junctions and/or
desmosomes. The loss of these connections can result in apoptosis or autophagy due to
anoikis (Gilmore 2005). Most cells within the body require cell-cell attachments to maintain
survival signals with the exception of hematological cells such as red blood cells and
immune cells. However, tumorigenic cells have typically undergone a process known as
epithelial-to-mesenchymal transition that allows them survive in the absence of cell contact
(Frisch and Cieply 2013).
If the tumor cell is able to survive the circulatory stresses it must then adhere to the
luminal side of the endothelial cells, and again transport across the endothelial barrier by
parracellular transendothelial migration in a process called extravasation (Li and King 2012,
Boelte and Ling 2010). If a circulating tumor cell is able to extravasate into the parenchymal
space of an organ that disseminated cancer cell may either lay dormant or begin

5

proliferating into a metastasis. Whether dormant or proliferative, disseminated cancer cells
must undergo a mesenchymal-to-epithelial transition (the reverse of EMT) and anchor
themselves to the organ in which they have extravasated (Gunasinghe and Hugo 2012).
Under the correct circumstances, growth factors etc. these cells may develop into life
threatening metastatic disease. Given the multi-step process of the metastatic cascade it is
a highly inefficient process with less than 0.01% of circulating tumor cells shed from the
primary tumor ultimately able of developing a distant organ metastasis (Fidler 1970, Fidler
2003).

Figure 1: Schematic of the Metastatic Cascade. The process of metastasis consists of multiple stages
each considered rate limiting. (Arshad, F., L. Wang, C. Sy, S. Avraham and H. K. Avraham (2010).

"Blood-brain barrier integrity and breast cancer metastasis to the brain." Patholog Res Int 2011:
920509). This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original
work is properly cited.
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Organotropism
Metastatic organotropism is the propensity for tumors of a specific origin to spread to
specific organs (National Cancer Institute). Based on basic science research, clinical
reports, and pathology reports the National Cancer Institute reports the following likely
metastatic organotropic organs for their primary cancer type (National Cancer Institute):
Cancer type

Main sites of metastasis*

Bladder

Bone, liver, lung

Breast

Bone, brain, liver, lung

Colorectal

Liver, lung, peritoneum

Kidney

Adrenal gland, bone, brain, liver, lung

Lung

Adrenal gland, bone, brain, liver, other lung

Melanoma

Bone, brain, liver, lung, skin/muscle

Ovary

Liver, lung, peritoneum

Pancreas

Liver, lung, peritoneum

Prostate

Adrenal gland, bone, liver, lung

Stomach

Liver, lung, peritoneum

Thyroid

Bone, liver, lung

Uterus

Bone, liver, lung, peritoneum, vagina

Figure 2: National Cancer Institute’s list of sites that cancer most commonly spread to from the
primary tumor. (National Cancer Institute. About Cancer. (n.d.). Retrieved August 07, 2016, from
http://www.cancer.gov/about-cancer)

In 1889 Dr. Steven Paget proposed that certain primary tumors had specific
metastatic tropism for specific organs, dubbed the seed-and-soil hypothesis. Paget stated
that tumors of specific origin release circulating tumor cells, the seeds, which can only grow
in a certain organ, the soil, based on the homeostatic factors found there. By performing
autopsies on patients he observed a non-random spread from primary tumors to specific
organs and deduced that this specific tumor organotropism was due to his seed-and-soil
hypothesis (Paget 1889).
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In the early 1900s a pathologist named Dr. Irving Zeidman found that circulating
tumor cells of specific tumor types had different morphological appearance and that certain
morphologies permitted the crossing of the endothelial capillary barrier leading to metastatic
growth (Ewing 1928). The observation that differing tumors release circulating tumor cells
with different morphologies leant to the seed-and-soil hypothesis in that certain
morphologies would be more likely to form emboli and more easily cross the endothelial
barrier and extravasate. These were not homogenous populations of circulating tumors cells
however and some cells did not appear to have the morphological attributes that would
allow them to cross the endothelial barrier (Ewing 1928). This observation was one of the
first examples of tumor heterogeneity and would be followed up with significant research
over the next hundred years showing that tumors are not clonal populations deriving from a
single dysplastic cell.
Tumor heterogeneity is defined by the fact that tumors do not generally consist of
clonal cells derived from a parent cell with X number of mutations, but rather a number of
different neoplastic cells with varying mutations conferring differing Darwinian survival
advantages (Marusyk and Polyak 2010). Based on the different pressures placed on the
cancer cells in the primary tumor such as hypoxia, excess lactic acid content, changes in
pH, different mutations will confer survival advantages that if left untreated will eventually
form into the ability to metastasize (Pepper and Maley 2009). Within a tumor different areas
are subject to different pressures, and within each organ these pressures are different, and
within an individual patient these pressures are further diverse. This multi-level difference in
selective pressures results in cancer in each patient being different from that of another
patient, even with a similar diagnosis. In large part this is the basis for today’s research into
more focused genetic therapies to target driver mutations. The heterogeneity of tumors
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further indicates that the cells that are able to metastasize are also heterogeneous in
nature, meaning that not all cells that metastasize are clonal either (Nowell 1976). However,
research has shown that despite heterogeneous emboli in the circulation the metastatic
tumors of melanoma where in fact clonally derived from a single parent cell (Talmadge
1982). This is additional evidence that only certain cells derived from the primary tumor
have the ability to survive and proliferate after leaving the primary tumor. This tumor
heterogeneity was further evidence that the cells able to enter the circulation had conferred
survival mechanisms that allowed them to propagate in specific environments, and thus
added weight to the seed-and-soil hypothesis. When all this evidence is amalgamated the
seed-and-soil hypothesis can be simply stated as cancer that can “metastasize to locations
that are biochemically and physiologically favorable for implantation and growth
(Ramakrishna 2013).”
In 1980 Dr. Isiah Fidler published a seminal paper supporting the seed-and-soil
hypothesis (Fidler 1982). After having worked with Dr. Irving Zeidman, Dr. Fidler performed
experiments in which he injected B16-F10 cells intravenously, subcutaneously or
intramuscular and observed their metastatic spread. The B16-F10 tumor cell line is a
melanoma line that underwent serial transplantation to isolate a highly metastatic form of
murine melanoma. Using both parabiosis and [125l]-5-iodo-2'-deoxyuridine cancer cell
labelling experiments Dr. Filder observed that despite circulating tumor cells being able to
reach both the kidneys and the lungs, they would only form metastasis in the lungs (Fidler
1970). This led the authors to conclude that metastasis did indeed follow the seed-and-soil
hypothesis given the presence of cancer cells in the kidney, but their inability to proliferate
due to an unfavorable environment.
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Prior to the seed-and-soil papers published in the mid-1900s, the predominant
theory of metastasis was put forth by Dr. James Ewing. In the 1930s Dr. Ewing submitted
an alternative hypothesis to seed-and-soil pertaining to metastatic disease in that cancer
cells spread to specific organs due predominantly to the mechanistic nature of the vascular
system (Ewing 1928). The vascular hypothesis asserted that once a cancer cell was able to
enter the circulation it would pass through the arteries into arterioles and then capillaries
and extravasate into parenchymal spaces. The organ that the cancer cell was able to
extravasate to was immaterial of the primary tumor but due to the nature of vasculature and
where the cancer cell happened to extravasate. The evidence for this was based primarily
on research showing that metastatic cells predominantly formed emboli in the capillaries of
metastatic organs, while similar emboli where found in the arterioles of organs that did not
form metastasis (Ewing 1928). Ewing proposed that the circulatory framework and
hemodynamics where responsible for the spread of cancer cells from their primary tumor.
For example, breast cancer was likely to spread to the lungs because of its proximity to
vena cava and the pulmonary arteries.
Recent studies using zebra fish models to visualize extravasation have also shown
that vascular mechanics are essential for the process of metastasis. Two studies (Stoletov
2010, Kanada 2014), one by Stoletov et al. in 2010 and Kanada et al. in 2014 showed that
when cancer cells where injected into zebrafish they could visualize the formation of emboli
in the arterioles and capillaries. The researchers opted to use zebrafish due to the ease of
visualization of their vasculature as compared to other animal models with non-opaque
dermal layers. They also show that the endothelium played an active role in the crossing of
the cancer cells across the vascular barrier and that when VEGF was depleted the cancer
cells were unable to intravasate, but could still extravasate.
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In addition to work in Zebrafish, significant gene research has focused on
organotropism, predominantly in breast cancer mouse models. Dr. Joan Massagué
compared the gene expression of human and mouse primary breast tumors in metastasis to
the bone, lung and brain and identified a number of genes that are associated with organ
specific metastasis. In their 2009 paper (Bos and Massagué 2009) they identified genes
that were associated with increased metastatic spread to the brain. The brain possesses a
particularly stable blood-brain barrier that is highly selective for permeabalization, none the
less metastatic cells have developed a means by which to cross this barrier, while many
chemotherapeutic drugs are unable to permeate the blood-brain barrier (Kreuter 2002). It is
worth noting that a significant number of the genes found in these three different studies are
overlapping, indicating that they may in fact not explain the organotropism of metastasis.
The modern study of organotropism has focused primarily on researching the gene
expression differences between different organs with metastatic disease and has not
focused on the non-organotropic organs or vascular signatures.
Both Paget’s and Ewing’s hypothesis offer explanations for the organotropic
properties of metastatic disease, and much like the nature versus nurture argument it is
most likely that both contribute to the spread of the disease. Since Paget and Ewing
significant research has been done on the vasculature indicating that there is in fact organ
specific differences. Although less well studied, organ specific vasculature may in fact marry
Paget’s and Ewing’s hypothesis as tumors of specific origin may affect organ specific
vasculature differently. The result would be different responses in vascular dysregulation in
varying organs and could contribute to the explanation for cancer tropism.
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Mouse Models for Metastasis and Organotropism
To continue the study of metastatic disease varying models have been designed to
faithfully replicate human metastasis. To date the most accurate models of metastasis are
found in mice that have transgenic induction of a tumor or are injected with a human or
mouse metastatic cancer cell line. The majority of transgenic cancer models can accurately
recreate primary tumor progression, but have been less successful at modelling metastasis
showing significantly decreased penetrance than in the human counterparts (Francia 2011).
Human derived cell lines necessitate injection into mice that are devoid of an active immune
system (NOD/SCID mice) so as to ensure that the tumors are not rejected, and thus
decreases the replication of the human model. This is especially important given recent
research showing the involvement of the immune system in tumor progression. There are a
number of mouse derived cancer cell lines that metastasize and this allows the orthotopic or
intravenous injection of mice with fully functioning immune systems that are known to
metastasize (Francia 2011). Although mice do differ from humans, the orthotopic injection of
mouse derived cancer cell lines does recapitulate the human model and is often used today
in the lab. Two such cell lines are the melanoma B16-F10 (Hart and Fidler 1980) and the
mammary fat pad 4T1 (Aslakson 1992, Pulasaki 2001) cell line to model breast cancer. The
B16-F10 cell was isolated by Dr. Fidler from a spontaneous melanoma that derived in
Black-6 mice and was serially transplanted from metastasis to produce a highly metastatic
line. The 4T1 cell line was similarly derived from a spontaneous tumor, this one formed in
the mammary fat pad of a BALBc mouse and was selected from numerous cells in the
primary tumor that showed high metastatic potential. There are also cell lines derived from
this same tumor that show less metastatic potential such as the 67NR cell line highlighting
the heterogeneous nature of tumors. As mentioned before Dr. Fidler utilized the B16-F10
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cell line to determine the organotropism of melanoma to the bone, brain, liver, and lungs.
Similarly, the 4T1 cell line when injected orthotopically has shown metastasis to the bone,
brain, liver, lung as does breast cancer in human patients. Numerous publications have
highlighted the spread of the B16-F10 and 4T1 tumor cell lines to their organotropic sites
providing weight to Paget’s seed-and-soil hypothesis.
More recent publications however have highlighted the capabilities of multiple mouse
cancer cell lines including B16-F10 and 4T1 to grow in non-metastatic sites when injected
directly or provided mechanistic support to reach non-organotropic site. A 2011 paper by Li
et al used hydrodynamic injections of B16-F1, 4T1 and Renca renal carcinoma cells to force
colonization of organotropic and non-organotropic organs. This procedure was typically
used to study the intravenous injection of DNA or RNAi into mice to illicit a genetic
phenotype. Hydrodynamic injections use high volume injections of anywhere between 810% of body weight to force an increase in pressure in the inferior vena cava which in turn
creates high internal hematological pressure. The increase in hemodynamic pressure
induces systemic endothelial leakage leading to increased extravasation and colonization of
the lungs, liver and the non-organotropic kidneys with B16-F1 and 4T1 cells. Contrary to the
findings of the seed-and-soil hypothesis this indicates that given the ability to enter the
perivascular parenchyma tumors can grow regardless of their etiology. Further evidence for
this was published in 2013 when Antonio et al. showed that 4T1 mammary fat pad cells
could be injected directly into the cortex of the kidney and grow and even metastasize from
the kidney to the lung. They further showed that by damaging the kidney with renal
ischemia reperfusion experiments they could provide a hypoxic environment that benefited
tumor metastasis and thus showed increased spread to the lungs. Furthermore, the human
cancer cell line MDA-MB-231 has also been shown to be capable of growth in the kidneys if
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it is injected in the renal capsule. In this model they were additionally able to show that the
MDA-MB-231 cells could invade from the renal capsule into the cortex of the kidney (Liu
2007).
The evidence for both Paget’s seed-and-soil and Ewing’s vasculature hypothesis are
numerous from both sides. Research has shown that tumors do indeed have a propensity to
spread to and grow in specific organs, while additional research shows that by by-passing
the endothelial barrier by forcing vascular leakage or direct injection to parenchyma allows
for non-organotropic growth. Rather than a one or the other argument, much like nature
versus nurture, both hypothesis are likely correct. However, rather than an effect on the
parenchymal space as argued by the existence of the pre-metastatic niche, it is the effect
that a primary tumor has on the organ specific vasculature that may determine metastatic
organotropism.
Vascular System
From the microbiological standpoint research into vascular biology has yielded
interesting developments since its description as the cardiovascular system by Hippocrates.
The endothelium is the inner most layer of the vascular tubing that makes up the circulatory
system. This one cell layer thick barrier separates the luminal side of the hematopoietic
system from the parenchymal space of organs, the abluminal perivascular side. While the
luminal side is always exposed to the rapid flow of the circulatory system the abluminal side
has profound differences depending on whether it is found in an artery, arteriole, metartiole,
capillary, venules, or vein. The layers of the vasculature consist of three layers, the tunica
intima (the innermost endothetial layer), the tunica media and the tunica adventia, the
outermost layer which connects the vessels to the surrounding tissue (Grey 2005,
Junqueira 2010).
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Arteries: Branching out from the heart these arteries are large elastic arteries. These
have an tunica intima similar to other aspects of the circulation. The tunica media consists
of thick layer called the internal elastic lamina that can stretch under the high pressures
found in the large arteries. The media of the arteries is the most distinguishing feature due
to its thickness and layers of smooth muscle fibers. The adventia is thinner than the media,
but contains immune cells, nerves and the vaso vorum (the vessel capillaries). These
branch into the muscular arteries which begin the distribution of blood to the organs (Grey
2005, Junqueira 2010).
Arterioloes: The muscular arteries repeatedly begin branching off into smaller and
smaller arterioles. Arterioles have a much smaller tunica media with only two smooth
muscle layers as compared to the 40-50 layers in the arteries. In this layer there is almost
no visible adventia layer. The arterioles denote the beginning of organ vasculature (Grey
2005, Junqueira 2010).
Capillaries: It is at the stage of the capillaries that the majority of nutrient and gas
exchange occurs with the surrounding organ in capillary beds. Capillaries have a single
endothelial layer forming the vascular tube, and being only one cell thick they allow only
single cell luminal transport at a time. They no longer have a smooth muscle layer. While
they are the smallest of the vessels they are almost the most numerous, making up 90% of
the vasculature (Figure 3) (Grey 2005, Junqueira 2010).
It is important to note that capillaries differ significantly in number and type based on
which organ they are found. Three different types of capillaries exist:
1) Continuous: These have no junctional spaces between endothelial cells and are
marked by well-defined tight junctions. They are the most numerous type of
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capillary and are found in muscle, lungs and exocrine glands. Their tightjunctions allow for the highly regulated transport of molecules across the vascular
barrier (Grey 2005, Junqueira 2010).
2) Fenestrated: The second type of capillary has what is described as a sieve-like
structure. These have many small openings along the endothelium allowing for
the transport of larger more extensive molecules. One would expect to find these
in organs that require rapid transport of multiple macro-molecules across the
vascular barrier such as the bodies filter, the kidney, food absorption in the
intestine and endocrine glands (Grey 2005, Junqueira 2010).
3) Discontinuous: Sinusoidal capillaries have large openings between endothelial
cells allowing for maximum exchange of molecules across the vascular barrier.
This discontinuous layer also allows for cells to cross the vascular barrier with
more ease than other capillaries and can thus be found in the liver and spleen
predominantly (Grey 2005, Junqueira 2010).

A

B

C

Figure 3: Schematic representation of A) continuous B) fenestrated and C) sinusoidal capillaries.
(Junqueira, L. C. U. a., J. Carneiro and A. N. Contopoulos Basic histology. A Concise medical
library for practitioner and student. Los Altos, Calif). Copyright Clearance 11611970.
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Pericytes: In addition to differences in types of capillaries, there is also a marked
variation in the coverage of pericytes in differing organ capillary vasculature.
Pericytes are a mesenchymal cell that wraps around the capillaries with foot
processes (Figure 4). They have been implicated in vessel stability, involvement
in contractile functions of the vasculature and have been shown to communicate
directly with the endothelial cells to which they are attached (Armulik 2011).
Through electron microscopy, immunofluorescence and histology percicytes
have been shown to wrap around endothelial cell capillaries at varying intervals
depending on the organ observed. In the retina the ratio of pericyte to endothelial
cell is close to 1:1, while in other tissues it may be closer to 10:1 and has yet to
be characterized for all organs (Armulik 2011). Thus, to date there has been no
extensive characterization of pericyte coverage comparison between each organ.
By reviewing publications that have used healthy controls of either kidney or
lungs stained with NG2, PDGFRb or Desmin it is evident that the kidney cortex
pericyte coverage is less than that of the pericyte coverage in the lungs (Armulik
2011). Regardless, this is an insufficient methods of analysis and an in depth
characterization of organ specific pericyte coverage is required.
Pericytes share a basement membrane with the endothelial cell on which
they are found and connect to the endothelial cell via an adhesion plaque and
peg-and-socket joints. The adhesion plaque consists primarily of fibronectin and
structurally resembles adherence junctions. The peg-and-socket joint on the
other hand has shown evidence of gap junctions (Armulik 2011). Particularly the
Connexin 43 gap junction has been shown to allow for communication between
endothelial cells and pericytes (Winkler 2011).
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Figure 4: The Structural and Molecular Connections between Pericytes and Endothelial
cells. (Winkler, E. A., R. D. Bell and B. V. Zlokovic (2011). "Central nervous system
pericytes in health and disease." Nat Neurosci 14(11): 1398-1405). Pericytes connect to
endothelial cells by Adhesion plaques and Peg-and-Socket joints. Right provided by
Nature Publishing group.
4007140417745

While pericytes where first identified in 1873 by Dr. Charles-Marie Benjamin

Rouget, research into their roles and function in normal physiology and pathology
has been limited to a select few researchers (Armulik 2011). One key issue with
pericyte research has revolved around a lack of unilateral agreement of
identifying markers. Currently the markers that have been validated for pericytes
are PDGFRb, NG2, CD13, aSMA, and desmin (Figure 5). PDGFRb and NG2
markers appear to be associated with pericyte recruitment to vasculature and
thus would seem to represent a possibly more immature stage of pericyte
(Armulik 2011). In contrast, Desmin, which is a contractile filament predominantly
expressed in the heart and muscle is a marker for mature pericytes and lends to
the generally accepted view that pericytes are involved in vascular constriction
and relaxation. It is important to note that in addition to being positive for the
following markers pericytes are also identified by their proximity to vessels. While
this can be done using an electron microscope, co-immunofluorescent staining is
necessary to show both pericyte markers and endothelial cells (Armulik 2011).
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Figure 5: Pericyte markers in murine research. PDGFRb, NG2, CD13, aSMA, and Desmin have all
been validated as murine markers of perciytes when associated with vasculature (Armulik, A., G.
Genove and C. Betsholtz (2011). "Pericytes: developmental, physiological, and pathological
perspectives, problems, and promises." Dev Cell 21(2): 193-215). Elsevier user license CC BY 4.0.

More recent research from Dr. Raghu Kalluri and Dr. Valerie LeBleu has
highlighted the role of pericytes in pathological states. The 2015 paper by Keskin
et al. showed the role of pericytes at different stages of tumor development by
selectively ablating proliferating pericytes at either early or late stage of tumor
development in a mouse model of breast cancer. In 2013 LeBleu et al. used
genetically engineered mouse models to fate map the source of myofibroblasts in
kidney fibrosis. She noted that the majority of myofibroblasts that contribute to
excess collagen in fibrosis are derived from local fibroblasts that differentiate into
myofibroblasts when exposed to certain cytokines. The remaining myofibroblasts
where derived from the bone marrow, endothelial cells undergoing EndMT and
epithelial cells undergoing EMT. However, they found that NG2 and PDGFb
pericytes while increasing during kidney fibrosis did not contribute to the
myofibroblast population within kidney fibrosis.
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The role of pericytes in lung fibrosis has also been characterized using similar
methodologies. In 2013 Hung et al. used Foxd1 tagged to Tomato red to show
that this population overlapped with PDGFRb positive cells and was thus a
pericyte population. Utilizing Bleomycin to induce lung fibrosis they showed that
this population contributed significantly to the fibrotic environment. However, in
2013 Rock et al. used NG2 expressing GFP under the control of Tamoxifen
inducible promoter to map the expression of pericytes during bleomycin induced
lung fibrosis. While they noted an increase in NG2 and PDGFRb positive cells in
lung fibrosis they did not see a costaining with aSMA, which would indicate the
transition from pericyte to myofibroblast. These conflicting reports underline the
issue of the need for agreement on pericyte identification.
Venules: After leaving the capillaries the circulation travels to the venules which also
have pericyte coverage. In post-capillary venules it has been found that these are the
primary sites that white blood cells diapedesis to parenchymal tissue during the
inflammatory process. The observation that white blood cells diapedesis specifically at
venules is of importance as it highlights the heterogeneity of endothelial cells. As the
venules increase in size towards veins, they show an ever increasing tunica media with
smooth muscle layers. A key characteristic of venules is they have a lumen that is far wider
in diameter than the thickness of their wall (Grey 2005, Junqueira 2010).
Veins: Unlike arteries veins have a relatively low pressure and thus move blood flow
back to the heart via the contraction of large smooth muscle around the vessel. This
function leads to the structural characteristic that veins have a prominent intima, a small
media and an adventia with large smooth muscle fibers for contraction (Grey 2005,
Junqueira 2010).
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The description of the vascular system highlights that most circulating tumor cell
extravasation occurs in capillaries responsible for organ oxygenation and nutrient supply. Of
interesting note is that despite the different capillary types this does not seem to correlate
with organotropism. For example, lungs have continuous endothelial capillaries whereas
kidneys are known to have fenestrated capillary endothelium. Given the presence of the
small holes and macromolecules crossing the endothelial border it would stand to reason
that the kidney should be a site of metastatic spread. However, as is apparent from Figure
2. the kidney is not a common site of metastatic spread in any primary tumor.
In addition to the endothelium of the lungs being continuous and that of the kidneys
being fenestrated both have unique vascular structure, but are highly vascularized. Blood
flow to the kidney enters via the renal artery at the hilus, flows into the interlobar artery, the
arcuate artery, the interlobular artery, then efferent arteriole of the glomerulus (Figure 6A)
and into the capillary tuft that forms the glomerulus (Figure 6B). From here blood flows out
of the glomerular tuft via the efferent arteriole and into either peritubular capillaries or the
vasa recta capillaries depending on the cortical location of the glomerulus. The peritubular
capillaries and vasa recta are the capillary structure of the kidney and ensure the cortex and
medulla of the kidney are highly vascularized as this is where water, Na2+, Cl- and other
ions are reabsorbed (Figure 6C). Blood then leaves the kidneys via veins with the same
names as the capillaries and arteries (Grey 2005, Junqueira 2010). The glomerular tuft is a
unique structure in that the capillaries in this structure are covered by a specialized cell
called a podocyte. Podocytes, similar to pericytes form foot processes around the
capillaries. These foot processes interdigit and form a filtration slit diaphragm, therefore in
addition to having to cross the endothelial layer, molecules and or cells also have to cross
the filtration slit diaphragm in order to enter the parenchymal space of the kidney. Research
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has shown that in some pathologies such as Alport syndrome red blood cells can cross the
endothelial layer in the glomerular tuft and enter the filtrate. Of interest is recent research
showing that the under other pathological conditions the slit-diaphragm can in fact tighten
with the increased expression of Claudin-1 between pedicel processes. This increased
expression of Claudin-1 would generate tight junctions that are less permeable to molecules
crossing the glomerular basement membrane barrier. However, upon leaving the efferent
arteriole only a single layer of capillary endothelial cells separates the circulation from the
parenchymal space in the peritubular arteries and the vasa recata. Finally, the hydrostatic
and osmotic pressure within the kidney is highly unique due to its filtration function. As the
glomerulus filters out ions but is not permeable to larger molecules such as Albumin there is
an increase in protein concentration within the plasma circulating in the kidneys. This
increases as water is absorbed by the proximal tubules and further ions are absorbed by
the tubules further along the nephron. Thus typical pressures in the vasculature of the
kidney are 20-30mmHg starting at the glomerulus and increasing as more ions are
transported out and the protein to plasma concentration increases (Grey 2005, Junqueira
2010).
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Figure 6: Vasculature and blood of the kidney. A) The
Glomerular tuft consists of capillaries surrounded by
podocytes that form the filtration slit diaphragm. B) Kidney
blood flow route. C) The peritubular capillaries and vasa
recta capillaries surround the kidney nephron for reuptake
of solutes and water (Junqueira, L. C. U. a., J. Carneiro
and A. N. Contopoulos Basic histology. A Concise medical
library for practitioner and student. Los Altos, Calif).
Copyright Clearance 11611970.

B

C

Relative to the kidney, the pressures in the lung are much lower ranging from 525mmHg (Grey 2005, Junqueira 2010). This allows the pulmonary vessels to be thin
allotting to the function of the lungs of transport of Oxygen and Carbon Dioxide within the
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alveolar ducts. The alveolar ducts are made up of alveoli that are capable of diffusing O2
and CO2 with blood in the surround capillary network (Figure 7). Blood leaves the left
ventricle of the heart and enters the lungs through the pulmonary artery where it branches
into capillaries that line the alveoli. Once reoxygenated the blood then returns to the heart
via the pulmonary vein and is ultimately pumped to the systemic circulation by the aorta
(Grey 2005, Junqueira 2010).

Figure 7: Vasculature of the Lung. Pulmonary capillaries allow for the diffusion of O2 and CO2. Type
I cells are primarily responsible for the gas diffusion. Type II cells are primarily responsible for the
production of surfactant to lubricate the lungs and prevent larger macromolecules crossing into
perivascular spaces. (Junqueira, L. C. U. a., J. Carneiro and A. N. Contopoulos Basic histology. A
Concise medical library for practitioner and student. Los Altos, Calif). Copyright Clearance
11611970.
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Angiogenesis and Angiopoietins
In 1779 surgeon Dr. John Hunter stated whenever “Nature has considerable
operations going on, and those are rapid, then we find the vascular system in a
proportionable degree enlarged (Eiseman 1984).” This observation was likely the first
description of the changes that the vascular system undergoes in both normal healthy
physiology beginning in utero and under many pathological conditions as well. The term
angiogenesis was coined first during the description of the formation of the placenta (Hertig
1935). However, it was not until 1971 when Dr. Judah Folkman published his work
describing the angiogenic process in tumor growth and cancer dependence on
angiogenesis that the importance of the angiogenic process became evident in both normal
and pathological conditions (Folkman 1971).
Vasculogenesis begins in utero and is the first aspect of embryo development
beginning after gastrulation to ensure the formation of the cardiovascular system. This
differs from angiogenesis in that it is the de novo formation of vessels from the mesoderm. It
can also occur post utero with the development of new vessels from angioblasts.
Angiogenesis on the other hand is the formation of blood vessels from existing vessels and
can occur via two differing mechanisms (Figure 8) (Hunt 2002):
1) Sprouting Growth: Sprouting angiogenesis occurs with the formation of a tip cell
from an existing capillary or vessel. This requires that surrounding basement
membrane be proteloytically degraded, that endothelial cells migrate and
proliferate, and ultimately that they are finally stabilized by mature pericytes. The
tip cell begins the process by budding off from the parent vessel and moving
towards the direction of a pro-angiogenic factor (such as VEGF). By utilizing
filapodia tip cells are able to degrade surrounding basement membrane and
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extracellular matrix to allow for the growth of vessels. Once the tip cell has
reached another vessel they anastomize and become a connected capillary with
a fully formed lumen. At this point pericytes will cover the endothelial cells and
ensure stabilization.
2) Inteussceptive Growth: In contrast to Sprouting angiogenesis, this process
involves the splitting of the vessels and lumen into two vessels. This was first
observed in the lung and is believed to be a more rapid form of angiogenesis.

Figure 8: The three methods of angiogenetic growth A) Classical capillary growth B)
Intussusceptive growth C) Longitudinal growth (Hunter, J. (2007). "A treatise on the blood,
inflammation, and gun-shot wounds. 1794." Clin Orthop Relat Res 458: 27-34).

Both forms of angiogenesis require either mechanical or growth factor stimulus to
begin the process of vessel growth. Evidence suggests that angiogenesis is a balance
process in that vessels are generally quiescent when there is a balance between proangiogenic factors and anti-angiogenic factors (Hunt 2002). Upon stimulation by either
mechanical means or by growth factors the scales can be tipped in one direction to initiate
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the angiogenic process. Mechanistically anything from cold, changes in blood flow pressure,
and shear stress can initiate angiogenesis. The presence of hypoxia in tissues is a key
initiator for angiogenesis (Hunt 2002). For example, exercise has been shown to initiate
angiogenesis in the heart and muscles, while excess adipose tissue development has
shown an increase in angiogenesis as well (Hunt 2002). While exercise is beneficial and
excess adipose tissue growth is considered non-beneficial this highlights the role of
angiogenesis in both normal and pathological processes. Angiogenesis is key in normal
wound healing, but is implicated in tumor growth and many other pathologies.
In association with the mechanical stimulus there are also a number of growth
factors that have been shown to be pro-angiogenic and anti-angiogenic (Figure 9). As
previously mentioned hypoxia is well established to induce the angiogenic process, and this
occurs when epithelial and stromal cells begin secreting pro-angiogentic factors in response
to hypoxia so as to ensure vessel growth to increase vascularization of that hypoxic area
(Hunt 2002).

Figure 9: Factors affecting angiogenesis as determined from in vitro
studies(Hunter, J. (2007). "A treatise on the blood, inflammation, and gunshot wounds. 1794." Clin Orthop Relat Res 458: 27-34).
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VEGF is considered a key indispensable growth factor for angiogenesis, but
nonetheless there are significant other factors that are involved in initiating and maintaining
the angiogenic process (Hunt 2002). The angiopoietins are an interesting angiogenic growth
factor as they come in multiple isoforms which work antagonistically to ensure a balance of
pro and anti angiogenic factors.
The tyrosine kinase receptor Tie-2 has been shown to be expressed predominantly
on endothelial cells and given that it has been shown through xray-crystalography studies
that both Angiopoietin 1 and Angiopoietin 2 are highly specific ligands for Tie-2 extensive
research has been focused on the effects of these angiopoietins on the vascular system
(Barton 2006). Significant research has shown that these two ligands act antithetically on
endothelial cells; Angiopoietin 1 stabilizes endothelial cell-cell interactions and limits
vascular permeability, Angiopoietin 2 has the opposite effect and decreases the endothelial
cell-cell interaction and leads to increased vascular leakage (Fagiani 2013). In combination
with increased levels of VEGF, Angiopoietin 2 has been shown to promote the angiogenic
process. While this may prove beneficial in normal healthy regulated physiology such as
wounds, in the pathological circumstances when excess Angiopoietin 2 is created this can
lead to systemic vascular leakage (Parikh 2006). In fact, excess expression of Angiopoietin
2 has been linked with poor prognosis for breast cancer patient metastatic disease (Keskin
and Kalluri 2015).
The angiopoietins work by binding to Tie-2 on endothelial cells and causing
intracellular downstream alterations that lead to either the stabilization or destabilization of
tight and adherent junctions between cells (Figure 10A, B). Angiopoietin 2, on binding to
Tie-2 increases the intracellular cytoplasmic levels of Rac to RhoA ratio, which in turn is
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believed to destabilize both tight junction complexes and adherent junction complexes
(Felcht 2012).

Figure 10: A) Representation of Tie 2 receptor and Angiopoietin structure. B) Representation of
Angiopoietin binding to Tie 2 (Fagiani, E. and G. Christofori (2013). "Angiopoietins in angiogenesis."
Cancer Lett 328(1): 18-26). Elsevier user license CC BY 4.0.

The antagonistic nature of the angiopoietins has led to research showing that under normal
physiological conditions the ratio of Angiopoietin 1 to Angiopoietin 2 shows higher levels of
the former. Conversely, when tissue damage occurs there is a rapid release of Angiopoietin
2. This occurs as Angiopoietin 2, with a half-life of 18 hours is stored in Weibell-Palade
bodies, which are small organelles found in endothelial cells (Rondaij 2006). Weibell-Palade
bodies were initially studied for their storage properties of Von Willibrand factor, a
fundamental clotting factor responsible for platelet binding during tissue damage. Later
research found that Angiopoietin 2 is also stored in Weibelle-Palade bodies and rapidly
released to tip that balance towards the pro-angiogenic process so as to re-vascularize
damaged tissue (Valentijn 2011). More recent research has shown that Weibelle-Palade
bodies are in fact a heterogeneous population in that some have Angiopoietin 2 stored,
while others seem to store P-selectin in an exclusive manner (Valentijn 2011). Lending
further evidence to the argument that vasculature in different organs may in fact respond
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differently to the same stimulus. In fact, on comparison of quiescent lung and kidney
endothelium it has been found that significantly higher levels of Angiopoietin 2 are
expressed in the kidneys (Gale and Yancopoulos 2002). This indicates that the kidneys
store Angiopoietin 2 in Weibell -Palade bodies at higher levels than the lungs.
Tight Junctions
Tight Junctions are the most apically located junctions that are responsible for cellcell contact and can be found in epithelial and endothelial tissues (Figure 12B) (Steed
2010). Typically, fibroblasts have been shown to not express tight junction proteins. Due to
the apical location of tight junctions in the endothelial cells they are key structures involved
in the regulation of vascular permeability (Anderson 2009). This is predominantly true for
large structures crossing the endothelial barrier such as immune cells or circulating tumor
cells. Whereas smaller molecules may be transported through endothelial cells via a
process known as transcellular transendothelial migration, larger structures such as cells
have been shown to almost exclusively cross by paracellular transendothelial migration
which is by passing between two endothelial cells (Erika 2009). In the presence of complete
tight junction complexes between endothelial cells there is a limited capability for cells or
larger macromolecules to cross the endothelial barrier (Figure 11). However, as mentioned
above when there is increased expression of pro-angiogentic growth factors such as VEGF
and Angiopoietin 2, the proteins of tight junction complexes become dissociated leading to
increase vascular permeability.

A

B

1. Figure 11: A) Electron Microscope Image of endothelial cells tight junction. B) Schematic
representation of transmembrane proteins responsible for tight junction formation. (Weiss,
N., F. Miller, S. Cazaubon and P. O. Couraud (2009). "The blood-brain barrier in brain
homeostasis and neurological diseases." Biochim Biophys Acta 1788(4): 842-857). Elsevier
user license CC BY 4.0.
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Tight junction complexes consist of multiple proteins bound together to form the
connection between two cells. The three transmembrane proteins directly responsible for
cell-cell binding are the claudins, occludin and the junction adhesion molecules (Steed
2010). Knock out experiments have shown that occludin is not required to form the tight
junction, but is involved in recruitment of the proteins to the tight junction complex (Yu
2005). There are three junction adhesion molecules (Jam1,2,3) that have also been shown
to be involved in stabilization of tight junctions and their knockout has led to increased
sensitivity to inflammation (Anderson 2009). The claudin family of proteins, of which there
are 27 isoforms in mus musculus (Ouban 2012), are the primary proteins that form tight
junctions. Research has shown that there are two types of claudins, tight junction forming
and channel forming. The tight junction forming claudins are responsible for the binding of
cells to adjacent cells and barrier function, while the channel forming claudins form
communication pores between adjacent cells, similarly to the gap junction connexins
(Krause 2008). Claudins have been shown to bind to claudins on adjacent cells, and
although every combination and permutation has not been tested it does appear that
claudins can bind to like claudins and some can also bind to different isoforms (Anderson
2009.
A
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Figure 12: A) Representation of transmembrane proteins interactions and binding to proteins of the
Tight Junction complex. B) Image depicting the apical localization of the tight junctions in both
epithelial and endothelial cells. C) Schematic of ZO-1 binding sites. (Bazzoni, G. and E. Dejana
(2004). "Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis."
Physiol Rev 84(3): 869-901). Permission is not required for this type of use.
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To localize to and stabilize tight junctions as transmembrane proteins the claudins,
occludin and the JAMs intracellular domains bind to the Zonnula Occludin 1 (ZO-1) protein
on specific domains (Figure 12A) (Bazzoni 2004). The claudins have been shown to bind
to the PDZ1 domain, the JAMs to the PDZ2 and PDZ3 and occludin binds to the GuK

domain (Bazzoni 2004). There is an additional SH3 domain that has been shown to be
necessary for PDZ binding stabilization (Lye 2010). Upon dissociation of the
transmembrane proteins from ZO-1, the ZO-1 protein delocalizes from the membrane and
moves towards the nucleus, although it’s function at and near the nucleus is not known
(Figure 12C) (Bauer 2010). In fact, it has been shown that during the process of EMT there
is a decrease in membrane ZO-1 as the tumorigenic cells gain the ability to survive without
cell-cell contacts (Zeisberg 2009).
Unfortunately, there has been limited research on the tight junctions that exist
between endothelial cells within different tissues and organs. The majority of tight junction
research has focused on epithelial cells and is inferred to endothelial cells. For example, it
has been shown that different claudins predominant at different stages along the epithelial

Figure 13: Representation of the location of the Claudin tight junction proteins along the kidney
nephron. (4.
Angelow, S., R. Ahlstrom and A. S. Yu (2008). "Biology of claudins." Am J Physiol
Renal Physiol 295(4): F867-876). Permission is not required for this type of use.
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cells of the kidney nephron (Figure 13) and that there is a kidney specific Claudin-10a that
is also expressed between vasa recta of the kidney (Angelow 2008). Additionally, at least
within the kidney it appears that there exist two isoforms of the ZO-1 protein, being either
positive or negative for an 80 amino acid alpha motif (Anderson 1993). While the epithelial
cells and parietal cells of the Bowman’s capsule express the α+ isoform the slit-diaphragm
and endothelial cells to express the α isoform.
A search of the literature found two papers in which they also show that the α
isoform is expressed in the endothelium of the lung as well. However, research into the
specific endothelial tight junction complex appears to be limited. The research that has been
done into the endothelial tight junctions has identified Claudin-5 as a key component of
vascular tight junctions (Escudero-Esparza 2011). Claudin-5 has been shown to be
dysregulated in gliomas (Karnati 2014), in the blood-brain barrier in brain metastasis
(Avraham 2014), and in lung pathologies such as acute lung injury leading to pulmonary
edema (Chen 2013). It has also been shown to be found in the endothelial cells of the
kidneys (Morita 1999). A 2014 study by Camire et al showed that when brain endothelial
cells are treated with 3-chloropropanediol there is a loss of tight junctions (Camire 2014).
Using a time course post-treatment, they showed that Claudin-5 expression goes down 90
minutes after exposure, but returns to normal levels after 120 minutes. By using PI3K and
AKT inhibitors they determined that the PI3K pathway is predominantly responsible for
Claudin-5 expression in brain endothelial cells. These findings implicate Claudin-5 as a key
regulator of vascular permeability in multiple organs.
While significantly more characterization of the differences in endothelial tight
junctions is required between each organ, there does appear to be organ specific
endothelial tight junction complexes regulating organ vasculature.
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Wound Healing, Cancer and Fibrosis
In 1986, the researcher credited with the discovery of VEGF, Dr. Harold Fisher
Dvorak wrote that “tumors are wounds that do not heal” (Dvorak 2015). The
histopathological similarities between tumors and the wound healing process led him to this
statement that has been used ever since. Since this declaration significant biochemical,
biophysical and histological research has indeed shown that wound healing, pathological
wound healing (fibrosis), and tumorigenesis have significant similarities (Arwert 2012).
The wound healing process is a well-characterized process that can be broken down
into four overlapping phases that begin at differing times post tissue insult. The process
begins with hemostasis and inflammation in which the body ensures the prevention of blood
loss through the secretion of clotting factors such as Von Willibrand factor, and the
recruitment of immune cells to the location of damage which are the first two steps. The
third phase is marked by proliferation with increased angiogenesis to revascularize the
wounded area and an increase in myofibroblasts to close the wound. The final stage is
called granulation in which the deposition and cross-linking of collagen to replace the
functional epithelial tissue that was damaged by the insult occurs (Gurtner 2008). The
deposited collagen tissue cannot perform the function of the epithelial tissue that it replaces
and acts like a scaffold as opposed to performing a parenchymal role. This would be akin to
an elevator being replaced by building rebar, the elevator no longer works but the building
stays standing. It is for this reason that skin scars do not grow hair, sweat or tan and is thus
the prime cause of thermodysregulation in patients with significant skin burns as their
epithelial tissue that was responsible for thermoregulation has been destroyed and replaced
with non-functional scar tissue (Church 2006). In the normal wound healing process this
process is self-regulating and once revascularization and granulation have occurred the
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pro-wound healing factors are downregulated and the process resolves (Gurtner 2008). In
the case of fibrosis and tumorigenesis these factors are constitutively upregulated and
overexpressed leading to a self-perpetuating wound healing process and thus the excess
deposition of collagen tissue, continued angiogenesis, and the destruction of surrounding
functional parenchymal tissue. When this occurs in a vital organ, if left unchecked can lead
to organ failure and death.
Given that the varying stages of wound healing involve angiogenesis and the
proliferation of myofibroblasts, the similarities between fibrosis and tumorigenesis become
evident (Figure 14A) (Arwert 2012). It is the kinetics that makes the key difference between
healthy wound healing and pathological fibrosis and tumorigenesis. A 2001 paper by
Kampfer et al characterized the mRNA expression levels of skin Angiopoietin 1 and
Angiopoietin 2 in mice with cutaneous wounds and found that after initial injury the levels
increased, but rapidly declined to basal levels after day 7. Conversely in mouse models of
diabetes the skin mRNA levels of Angiopoietin 2 did not resolve after day 7 (Kämpfer 2001).
Fibrosis research has shown that due to the presence of fibrotic tissue in patients with liver
cirrhosis, chronic gastritis, and other fibrotic disorders predisposes them to the development
of cancer in the afflicted organ. For example, liver cirrhosis is a significant risk factor for
hepatocellular carcinoma (Bugianesi 2002). Thus the presence of excess wound healing
factors promotes the development of tumor growth (Figure 14B, Figure 15).
Numerous studies focusing on individual factors increased in the fibrotic environment
have shown their pro-tumorigenic properties. A prime example of this is Lysyl Oxidase
(LOX) and its significant increase during fibrosis. Increase LOX during fibrosis occurs as it is
involved in and necessary for proper cross-linking of newly developed collagen fibers. Dr.
Janine Erlner published works showing in Bleomycin induced fibrotic lungs and Carbon
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Tetrachloride induced fibrotic livers there was increased metastatic spread from 4T1 cells to
those fibrotic organs as compared to their non-fibrotic controls (Cox 2013).
A

B

Figure 14: A) Diagrammatic comparison between the wound healing process and the process of
tumor growth and invasion. B) A Comparison between wound healing and cancer. (Arwert, E. N., E.
Hoste and F. M. Watt (2012). "Epithelial stem cells, wound healing and cancer." Nat Rev Cancer
12(3): 170-180). Right provided by Nature Publishing group.
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Furthermore, they showed that high levels of secreted LOX from primary tumors alters the
environment of organotropic organs such as the bone to develop a pre-metastatic niche
(Cox 2016). They also found that secreted LOX binds to fibronectin in the lungs as similar to
their bone findings prepares the lungs soil for seeding from the primary tumor. LOX is one
of many pro-tumorigenic factors that have been published showing similarities between the
fibrotic environment and the tumor microenvironment (Cox 2016).

Summary

Figure 15: Table showing the cytokines implicated in both wound healing and in the cancer growth
and development. (Arwert, E. N., E. Hoste and F. M. Watt (2012). "Epithelial stem cells, wound
healing and cancer." Nat Rev Cancer 12(3): 170-180). Right provided by Nature Publishing group.
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Despite the fact that metastasis is the primary cause of mortality in patients with a
cancer diagnosis, there are limited therapies to treat metastatic disease. Even armed with
the knowledge of where specific tumors are likely to spread to we still have limited
knowledge about the etiology of organotropism and why certain organs are more
susceptible to metastatic spread over others, for example why are the lungs a common site
of metastasis while the kidney is rarely ever found to have metastatic disease. Both are
major sites of blood flow, have significant capillary coverage, high perfusion rates and
require the diffusion of macromolecules across the endothelial barrier for function.
Furthermore, direct injection to bypass the endothelial barrier or mechanical manipulation of
systemic vasculature has shown that cancer cells can grow in non-organotropic
parenchyma if able to reach that environment. This clearly indicates that if cancer cells are
able to cross the endothelial barrier that they will likely able to grow in the parenchymal
space of whatever organ they disseminated to. This appears to be a contradiction to
Paget’s generally accepted seed-and-soil hypothesis.
Rather than seemingly contradicting Paget or Ewing’s hypothesis, an amalgamation
of the two theories might help to explain metastatic organotropism. The vascular system is
not a homogenous system, and it is clear that the vasculature of different organs is not only
physically different but may also respond differently to the same secreting cytokines. This
would indicate that metastatic organotropism is likely due at least in part to the
heterogeneous nature of organ specific vasculature and its response to circulating protumorigenic factors.
Such pro-tumorigenic factors can be found in the wound healing process, but are
found both in excess and for chronically longer durations post insult during fibrosis,
tumorigenesis and other pathological states. During these pathological states these factors
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are secreted into the circulation and will thus have systemic effects. Cytokines once in
circulation will make direct contact with the luminal side of the endothelium prior to any
other cell type. Given that these cytokines are pro-angiogenic and are by all essential
reasoning bombarding the endothelium, one would expect there to be wide ranging
systemic organ damage in any disease which leads to excess circulating fibrotic or
tumorigenic factors. However, that is not the case. For example, in patients with Sepsis,
who have increased levels of circulating Angiopoietin 2, TNFa and TGFb, all factors
associated with pro-fibrosis and pro-tumor growth, the lungs are predominantly effected
leading to an increase in pulmonary edema due to vascular leakage. While some other
organs are also affected, not every organ appears to have vascular alterations in these
circumstances leading to further evidence that the endothelial responses to cytokines are
organ specific.
Here we hypothesize that organ specific vasculature responds differently to the
same cytokines in circulation. Thus in the presence of tumor or fibrosis secreted cytokines
only certain organs would show altered vasculature that increases their vascular
permeability and increases the likelihood of paracellular transendothelial migration of
circulating tumor cells. By inducing fibrosis in both organotropic lungs and non-organtropic
kidneys in mouse models of breast cancer we can determine whether the pro-tumorigenic
fibrotic environment is capable of redirecting metastasis to a non-tropic organ. Furthermore,
this allows us to determine the differential organ specific vascular response of excess
secreted cytokines from fibrosis or tumors.

39

Chapter 2 Material and Methods
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Anesthesia: Mice will be anesthetized with Ketamine/Xylazine (Ketamine (100mg/kg body
weight); Xylazine (10g/kg body weight)). The duration of the anesthesia is 30-60minutes.

Analgesia: Bupreorphine will be given subcutaneously (0.1mg/kgBW in 100ul PBS) prior to
skin incision, then at 12 and 24 hours after operation.

Wound Induction: The wound induction is a unilateral 8mm dorsal wound that resolves in
10-17 days. The right dorsal aspect of the mice will be shaved and the skin prepped with
betadine and alcohol. Approximately 1cm right from the dorsal central axis of the mouse a
Miltex 8mm Sterile Disposable Biopsy Punch will be used to remove the dermal layer down
to the peritoneum, without interrupting the peritoneum. The wound will be carefully cleaned
with iodine post surgery and the mouse monitored for signs of infection.

Bleomycin: Intratracheal Bleomycin injections will be used to induce lung fibrosis. Place the
mouse supine on a surgical board. Elevate the surgical board to at least a 45-degree angle
so that the mouse’s head is elevated above its thorax. A 1 cm incision will be made
vertically along the trachea ensuring clear visualization of the muscle layer. The
Sternohyoid muscles will be gently displaced to reveal the trachea. Using fine tip tweezers,
the tracheal peritoneal layer will be removed so as to visualize the tracheal cartilage rings.
Using a 28-gauge needle 100ul of Bleomycin (15 units) will be injected between two
cartilage rings. Confirmation of a successful injection will be visualized by a momentary
pulmonary distress. Pulmonary distress should resolve within 5-10 seconds. The
Sternoyhoid muscles will be replaced and the epidermal layer will be sutured with
continuous non-absorbable sutures. The wound will be cleaned and the mice monitored.
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UUO: UUO or unilateral ureteral obstruction (mild to severe fibrosis that does not resolve,
the mice are euthanized at 10 days’ post UUO). One 1.5 cm long longitudinal incision will be
made on the abdomen, approximately at 0.5cm left of the nipples on the left flank of the
animal (starting at the level of the 4th set of nipples and continuing 1.5cm toward the head of
the animal and will not exceed 1.5cm). The skin will be gently separated from the
peritoneum to expose the peritoneum. A second incision will be made in the peritoneum,
longitudinally starting at the level of the 4th nipple and continuing 1cm toward the head of
the animal, not to exceed 1cm in total length. The abdominal cavity is now open and the
organs gently moved to expose the ureter. The ureter is then ligated with non-absorbable
nylon string at 0.5 cm below the kidney. The peritoneum is then sutured with simple
interrupted absorbable sutures while the skin is sutured with simple interrupted nonabsorbable sutures or surgical staples. Control mice include sham operation, which consists
of exposing the ureter and closing peritoneum and skin.

Breast Pad/ Mammary Gland Injection: Bilateral incisions will be made on the abdomen of
the mice without interrupting the peritoneum. Each incision will begin towards the hind leg
of the animal between the 4th and 5th sets of nipples and extend towards the head of the
animal no more than 1.5 cm. The skin will then be gently separated from the body cavity in
order to expose the breast pad/mammary fat glands that are situated on the underside of
the skin. Tumor cells (500,000 cells/20ul PBS per breast pad) will be injected into each
breast pad using a Hamilton syringe fitted with a 25G needle. The abdominal incision will be
closed using either simple interrupted vicryl sutures with non-absorbable nylon string or
surgical staples.
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Retroorbital Injection: Cell injections will be in 100ul volume and 500,000 cells in PBS
retroorbitally.

Breast Pad/Mammary Gland Injection+No Surgery/Wound/Sham/UUO: Mice will be
implanted with 4T1 breast cancer cells into the mammary fat pads. When the tumors reach
500mm3, cohorts will receive 1) no treatment, 2) Wound Induction, 3) Sham surgery, 4)
UUO surgery, 5) Sham+IgG, 6) UUO+IgG 7) Sham+anti- Angiopoietin 2, or 8) UUO+antiAngiopoietin-2. All Mice will be sacrificed 10 days following surgery including control mice.

Retroorbital Injection+No Surgery/Wound/Sham/UUO: Mice will be retroorbitally injected
with 4T1 breast cancer cells. On the same day the mice will be also receive 1) no treatment,
2) Wound Induction, 3) Sham surgery, 4) or UUO surgery. All Mice will be sacrificed 10
days following surgery including control mice.

Retroorbital Injection+Recombinant Angiopoietin 2 Treatment: A cohort of mice will receive
2 intraperitoneal injections of 100ug recombinant mouse Angiopoietin 2 (7186-AN-025). The
first injection will be given at day –1; the second injection will be given at day 3. The control
group will receive PBS only. The mice will be euthanized at day 10. An additional cohort will
be retroorbitally injected with 500,000 cancer cells at Day 0. The mice will be euthanized at
day 10.

Mouse Monitoring: The mice will be euthanized 10 days post wound induction. The dermal
wound will be monitored daily for infection and 10% weight loss together with significant
decreased activity/reactivity will be used to determine whether mice require euthanasia
before the 10-day sacrifice time point. Tumor bearing mice will be monitored daily, tumors
measured, and tumors necrosis, 10% weight loss together with significant decreased
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activity/reactivity will be used to determine whether mice require euthanasia before the 10day sacrifice time point. All mice be euthanized upon tumor size reaching 1500mm 3.

Tissue collection during euthanasia: 1 hour prior to euthanization mice will be injected with
FITC-Dextran 70,000kD at 100 mg/ml (46945). Mice will be anesthetized with
Ketamine/Xylazine and cervically dislocated after collection of whole blood.

Retroorbital Whole Blood Collection: Utilizing a glass pipet, 10ul of heparin will be collected
into the pipet. The tip of the glass pipet will be inserted into the medial canthus of the eye
under the nictitating membrane. Light pressure will puncture the sinus membrane and blood
will begin to flow into the glass pipet.

Tissue Collection: Post cervical dislocation, the mouse will be secured to a dissection board
so its abdomen is exposed, and sprayed lightly with 75% ethanol to wet the fur and skin to
prevent contamination. Perform an incision 1cm above the central axis of the genitalia, then
continuing towards the mouse’s head will expose the abdominal cavity and the rib cage.
The femoral artery will be perforated to allow blood to flow. Using surgical scissors, the rib
cage will be removed exposing the lungs and heart. A 10ml syringe with PBS and a 20gauge needle will be inserted into the left ventricle of the heart and gentle pressure will be
placed on the syringe. Successful perfusion will be evident by clear PBS flowing from the
femoral perforation, and paling of the liver, kidneys, and lungs.

Formalin Fixed Paraffin Embed: All tissues for FFPE will be collected into tissue cassettes
and placed in formalin jars. They will be processed overnight and embed in paraffin no more
than 2 days later.
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Snap Frozen Tissue: All snap frozen tissue will be immediately placed in a 1.5ml Eppendorf
Tube and put into liquid nitrogen. All snap frozen samples will be stored at -80C.

Lungs: The left lung lobe will be collected for FFPE. The right superior and inferior lobes will
be collected for OCT. The middle and post-caval lobe will be snap frozen.

Liver: The median lobe will be collected for FFPE.

Kidney: The fibrotic and contralateral kidney will be removed and separated into anterior
and posterior sections using a surgical blade. The anterior of each kidney will be collected
for FFPE. The posterior kidney will be separated into apical and basilar sections. The apical
section will be processed for OCT and the basilar will be snap frozen.

Tumor: Tumors will be weighed upon resection. Tumors will be separated into anterior and
posterior sections using a surgical blade. The anterior tumor will be collected for FFPE. The
posterior tumor will be separated into proximal and distal sections. The proximal tumor will
be processed for OCT. The distal tumor will be snap frozen. Sections of all remaining tissue
will be collected for FFPE and snap frozen tissue.

Angiopoietin 2 ELISA: Whole blood will be spun down at 1500rpm for 5 minutes at 4C.
Serum will be transferred to another 1.5ml Eppendorf tube. Angiopoietin-2 ELISA will be
performed on serum using Abcam Angiopoietin-2 Mouse ELISA kit (ab171335).

Metastasis Analysis: At least 2 5um thick representative sections of the lungs from each
mouse will be stained with H&E. These slides will be scanned using Panoramic 250 Flash
II. Each slide will be analyzed for metastasis on Panoramic Viewer. Metastatic burden will
be calculated by dividing the area of metastasis by the total area of the lung. Differential
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analysis will performed using Prism. Statistical analysis will be a unpaired 1-Way Anova
comparing the mean of each group to the mean of each other group at 95% confidence to
determine statistical significance.

Immunofluorescence: 4 images will be taken per slide. Using Zeiss Zen Blue software, a 10
by 10 grid will be overlayed on the image. This grid will allow us to determine the percent of
fluorescence positivity in each image taken based on the analysis we are performing. For
analysis requiring visualization of structural components a brightfield image will also be
used to determine specific histological structures. Statistical analysis will be a unpaired 1Way Anova comparing the mean of each group to the mean of each other group at 95%
confidence to determine statistical significance.

Quantitative (Real-Time) Polymerase Chain Reaction (qPCR): RNA will be isolated from
snap frozen tissue using traditional Trizol extraction methods. RNA will be measured using
Nanodrop for purity. cDNA will be synthesized using High-Capacity cDNA Reverse
Transcription Kit (4368814). qPCR will be performed using SYBR Green Real-Time PCR
Master Mixes (4367659) on QuantStudio™ 7 Flex Real-Time PCR System from
ThermoFisher.
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Fibronectin F
Fibronectin R
Col1α1 F
Col1α1R
LOX F
LOX R
TNFa F
TNFa R
FGF F
FGF R
VEGF F
VEGF R
Ang2 F
Ang2 R
CD31 F
CD31 R
GAPDH F
GAPDH R
TGFβ1 F
TGFβ1 R
Tie 2 F 1
Tie 2 R 1
Tie 2 F 2
Tie 2 R 2

GCTCAGCAAATCGTGCAGC
CTAGGTAGGTCCGTTCCCACT
GCTCCTCTTAGGGGCCACT
CCACGTCTCACCATTGGGG
TTCTTCTGCTGCGTGACAACC
AATAGGGGTTGTCGTCGGAGT
CCAGTGTGGGAAGCTGTCTT
AAGCAAAAGAGGAGGCAACA
GCGACCCACACGTCAAACTA
TCCCTTGATAGACACAACTCCTC
AAAGCCAGCACATAGGAGAGATGAG
CTCGAAGAGTCTCCTCTTCCTTCATG
CAGCCACGGTCAACAACTC
CTTCTTTACGGATAGCAACCGAG
TGCACAGTGATGCTGAACAA
CCATGAGCACAAAGTTCTCG
GCAAGGTGTATGAATCTGTGCT
TCAAGGTAACAAAGAGTGCCA
CACTGGAGTTGTACGGCAGTG
AGAGCAGTGAGCGCTGAATC
GAGTCAGCTTGCTCCTTTATGG
AGACACAAGAGGTAGGGAATTGA
CGGCAGGTACATAGGAGGAA
TCACATCTCCGAACAATCAGC

Statistical Analysis: Data are represented as the mean ±SEM. *p < 0.05, **p < 0.01, ****p <
0.0001. ns, not significant. Analysis of two samples or indicated by comparison bars was
performed by Unpaired Student’s T-test. Multiple group analysis was performed using Oneway Anova.

Cell Culture: Renal and lung endothelial cells were obtained from the laboratory of Dr.
Isaiah Fidler and cultured as previously described ((Langley and Fidler 2003). For
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Angiopoietin 2 stimulation, 1ug of murine recombinant Angiopoietin 2 (7186-AN-025) was
added to the culture media for the indicated times. 4T1 cancer cells where tagged with GFP
and grown to 80-85% confluence. Cells where trypsinized and washed in PBS prior to
intravenous or orthotopic injection.

Quantification of metastatic burden and tumor necrosis: Hematoxylin and eosin staining of
the lung and kidney sections from paraffin-embedded tissue was generated. Image of an
entire lobe was obtained using the Panoramic 250 Flash III slide scanner. Metastasis were
identified using via histopathological analysis based on H&E staining and metastatic area
was quantified using Panoramic Viewer software as a percentage of total lung area. High
magnification images of the metastatic area are provided for each lung photomicrographs.

ELISA: Blood was collected at the time of euthanasia and 200ul was spun down at 1500rpm
for 5 minutes. Serum was separated and stored in -80C. Samples were thawed and 20ug
was diluted in the sample diluent buffer provided in the Angiopoietin 2 Mouse ELISA kit
(Abcam ab171335) and the ELISA was then carried out following the manufacturer’s
directions.

Western Blot: Cells where grown on 6cm dishes and treated as indicated. Cells were
washed with PBS and removed from the dish using a cell scraper and transferred to a 1.5ml
Eppendorf tube. Cells where spun down at 1500rpm for 5 minutes and supernatant
removed. Cell pellet was resuspended in 200-300ul of RIPA buffer and sonicated every 10
minutes for 30 minutes at 4C. Lysate was spun at 12,000rpm for 10 minutes and
supernatant was transferred to a new 1.5ml Eppendorf tube. Protein concentration was
measured using BCA assay reagents (Pierce). Western blot was run using standard BioRad
protocol. Membranes were blocked in 5% milk in PBS for 1 hour and incubated in Actin
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(1:1000 Cell Signaling 4970), pTie2 Tyr1108 (1:100 Thermo Fischer PA5-38339) and pERK
(1:500 Cell Signaling 9101) overnight in 4C. Membranes were washed and incubated in
secondary HRP conjugated antibody and exposed.

Immunofluorescence/ Immunostaining: Harvested tissues, tumor, lungs, and kidneys, and
skin were fixed in 10% neutral buffered formalin, dehydrated and embedded in paraffin. For
Sirius Red the deparaffinized tissues were stained in hematoxylin for 8 minutes, washed for
10 minutes and then stained in Sirius Red solution for 1 hour. Slides where then scanned
using Pannoramic 250 Flash III slide scanner and quantified on Phostoshop software using
a 10 by 10 grid to count positive areas for ≥3 fields/tissue per x20 image. Alternatively,
deparaffinized tissues were incubated in 10mM citrate buffer (ph 6.0) for 15 minutes at 95C
prior to blocking with 4% Cold Water Fish Gel in PBS. Tissues where incubated overnight in
following blocking in αSMA(1:500 Sigma C6198), Claudin 5 (1:100 Thermo Fischer 352500), Ki67 (1:500 Abcam ab15580), and Isolectin B4 (1:500 Thermo Fischer I21411)
followed by secondary fluorescent antibodies. Slides were mounted with DAPI to label
nuclei. Positive staining was quantified in ≥3 visual fields/tissue at x63 or x100 using
Photoshop software by placing a 10 by 10 grid to count positive areas or costaining.
Statistical analysis was done using the average staining per tissue. Stainings were
visualized on a Zeiss microscope. For the cell culture staining cells where grown on 8 well
chamber slides and treated as indicated with either PBS or murine recombinant
Angiopoietin 2. Cells where washed in PBS and fixed for 10 minutes in 4%
paraformaldehyde then blocked for 1 hour in 4% Cold Water Fish Gel in PBS. Cells where
incubated overnight in ZO-1 (1:100 Thermo Fischer 61-7300) and Phalloidin (1:1000
Thermo Fischer T7471).

49

Microarray analysis and quantitative real time PCR analysis: Total RNA was isolated from
healthy and wounded skin, healthy and fibrotic lungs and healthy and fibrotic kidneys Trizol
(Invitrogen) and RNA was extracted according to manufacture’s instructions.. An equal
amout of RNA was submitted from each cohort (n=3) to the Microarray core facility at MD
Anderson. Microarray analysis was performed using Mouse Ref8 Gene Expression
Beadchip (Illumina) software. Ingenuity Pathway Analysis (IPA) was performed on the
microarray data set, with a threshold of 1.2 and 1.5 fold. For RT PCR analyses, tissues
were homogenized in Trizol (Invitrogen) and RNA was extracted according to manufacture’s
instructions. cDNA was generated using High Capacity cDNA Reverse Transcriptase Kit
(Applied Biosytems). Gene expression was determined using Applied Biosystems 7300
Sequence Detector System and SYBR green as the fluorescence reporter. Measurements
were standardized to the housekeeping gene (CD31 or GAPDH).
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Results
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Chapter 3: Kidney and Lung Fibrosis express similar pro-tumorigenic factors
Fibrosis and the tumor microenvironment have been shown to share a number of
biochemical and biophysical similarities including secreted cytokines. Previous research has
shown that fibrotic environments are pro-tumorigenic for primary tumor growth and can also
enhance metastatic growth to organotropic organs. Furthermore, the fibrotic environment
and the pre-metastatic niche have been also been shown to be similar and the premetastatic niche has been implicated as a potential driving factor towards organotropism.
The majority of metastasis and organotropic research has been focused on the tropic
organs while limited research has focused on the organs that rarely develop metastasis.
Here we choose to focus not only on the tropic organs within breast cancer, but to also
determine if we created a fibrotic, and thus pro-tumorigenic, pre-metastatic niche
environment in a non-organotropic organ could we re-route metastasis to that organ. Given
previous publications implicating the increased levels of TGFβ, LOX, TNFα, Collagen,
αSMA among other factors in the fibrotic environment, tumor microenvironment and premetastatic niche, we aimed to determine whether this was sufficient to re-route metastasis
to a non-organotropic organ.
For the purposes of this study we choose to utilize two well-established mouse
models of metastatic breast cancer. The mouse derived 4T1 mammary fat pad cancer cell
line and the MMTV-Pymt models have both been shown to metastasize to multiple organs
including the lung, liver and brain with similar tropism to human breast cancer. The
advantage of these models is that they both have consistent temporal tumor growth rates.
This allows for the induction of specific treatments at known tumor sizes providing for a
consistency across the two models. Furthermore, both of the models are in the BALB/c
background allowing for the comparison of the two different breast cancer models. Currently
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there are no studies utilizing these models to determine whether they can be rerouted to
metastasize to a non-tropic organ. It has been shown that direct injection of 4T1 cells into
the kidney can form a tumor within the cortex indicating that if capable of entering the
parenchymal space of the kidney these cells would be capable of forming a metastatic
nodule.
To elucidate the contribution and control of the fibrotic environment on metastasis
we evaluated three models of tissue damage in 4T1 and MMTV-Pymt tumor bearing mice.
By inducing a cutaneous wound, lung fibrosis and kidney fibrosis we can observe a normal
resolving wound, an organotropic fibrosis and a non-organotropic fibrosis effect on
metastatic spread in breast cancer. Given that clinically surgery, a wound, has not been
shown to enhance metastasis and other research has indicated that pro-fibrotic factors go
down by day 7 in normal resolving wounds in mice the wound will act as the control for
normal kinetics. Comparison of the wound to the lung fibrosis and kidney fibrosis allows us
to compare acute normal wound versus chronic fibrotic damage. Utilizing Bleomycin to
induce lung fibrosis we aim to develop a pro-tumorigenic environment in an organotropic
organ, while surgically induced kidney fibrosis will act as the non-organotropic organ.
Based on the pro-tumorigenic and pro-metastatic nature of the fibrotic environment
and its secreted cytokines, we hypothesized that both lung fibrosis and kidney fibrosis
would have the necessary factors to enhance metastasis in a systemic manner. In
accordance with previous studies we expect to see an increase in metastasis to the fibrotic
lung, and given the induction of a similar pro-tumorigenic environment in the fibrotic kidney
we would hypothesize that this would induce metastatic growth in the damaged nonorganotropic organ.
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Histopathological characterization of cutaneous wound, lung fibrosis and kidney
fibrosis shows increased collagen deposition and aSMA+
To understand the role of the fibrotic environment in breast cancer metastasis we
began by evaluating and comparing the pro-tumorigenic factors expressed in a resolving
wound, lung fibrosis and kidney fibrosis. Cutaneous wound skin at day 6 post injury (an
open wound), Bleomycin induced fibrotic lungs, and surgically induced fibrotic kidneys
where harvest at day 10 post insult. The insulted organs where each stained with H&E,
Sirius Red and immunofluorescently stained with aSMA. Morphometric analysis for Sirius
Red and aSMA was performed comparing each fibrotic organ with its healthy control. Sirius
Red is a cationic dye that binds by reacting to the basic groups in collagen. The dye binds
to the collagen molecules in a parallel orientation, which results in an increased bifringency
and is counterstained with pictoric acid and hematoxylin for nuclear stain. An increase in
positive red area indicates an increase in collagen. There is a significant increase in Sirius
Red positive areas in the skin wound at day 6 and both lung and kidney fibrosis (Figure
16B,D,F,H). Additionally, aSMA, a marker for the collagen depositing myofibroblasts is also
significantly increased in the day 6 wound, and lung and kidney fibrosis. (Figure 16C,
E,G,I). Taken together these results indicate that an open wound, lung and kidney fibrosis
all show increases in the production of fibrotic tissue.
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Figure 16: Histology of fibrosis in skin, lung and kidney. A) H&E of healthy skin, wounded skin,
healthy lung, fibrotic lung, healthy kidney, and fibrotic kidney. B) Sirius Red of healthy skin,
wounded skin, healthy lung, fibrotic lung, healthy kidney, and fibrotic kidney. C) aSMA
immunofluroscence of healthy skin, wounded skin, healthy lung, fibrotic lung, healthy kidney, and
fibrotic kidney. D) Quantification of skin Sirius Red. E) Quantification of skin aSMA. F) Quantification
of lung Sirius Red. G) Quantification of lung aSMA. H) Quantification of kidney Sirius Red. I)
Quantification of kidney aSMA. Scale bar=25um.Data are represented as the mean ±SEM using
Student’s T-test for *p < 0.05, **p < 0.01, ****p < 0.0001. ns, not significant.
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Fibrotic environments show sustained increased chronic expression of
pro-tumorigenic factors
Given that healthy wounds begin resolving and are typically fully closed in healthy
mice by day 10-17, versus fibrosis which persists beyond day 10 post insult we performed
Illumina gene expression arrays on skin at day 6 and day 17 post injury, and on fibrotic and
healthy lungs and kidneys. Using previous publications, we compiled a list of genes shown
to be present in the pre-metastatic niche and to be pro-tumorigenic. The open wound and
closed wound were normalized to healthy unwounded skin, while the fibrotic lung and
fibrotic kidney where normalized to a healthy respective organ. By comparing the differential
gene expression levels in a healthy open wound versus a healthy closed wound it is evident
that the pro-tumorigenic genes do not significantly increase their expression and/or return to
basal levels once the wound is closed. Conversely, when both the fibrotic lung and fibrotic
kidney are compared to their respective healthy control organ at day 10 post insult a
number of genes associated with pro-tumorigenic growth are still upregulated (Figure 17).
To confirm the chronic upregulation we performed qPCR on select genes to confirm their
upregulation at day 10 in the kidney fibrosis models (Figure 18).
The sustained increase in similar pro-tumorigenic factors in the fibrotic lung and
kidney versus the resolved factors in the wound will enable us to test the effects of forming
a pro-tumorigenic environment in the tropic and non-organotropic organ.
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Healthy
Open
Closed Healthy Fibrotic Healthy Fibrotic
Skin
Wound Wound
Lung
Lung
Kidney
Kidney
3.07516 2.99499 3.51942 3.19066 3.96621 3.67244 4.07286

S100a9 2.52799 2.95912 2.47023 2.96241 3.57985 3.51871 3.91676
Col2a1

0.82962 1.28102 1.07378 1.01479 2.87156

2.2508

3.89936

Egfr

1.48372 1.31751 1.54426 1.14661 2.82625 2.25604 3.85253

Tnfsf11

1.11608 1.32976 1.31108 1.98621 2.57638 3.19077 3.80382

Col4a5

2.42596 2.17558 2.09437 1.92902

2.5956

2.78117 3.65615

Fn1

1.74539 1.64242 2.16098 2.45451 3.01414 3.56865 3.64291

Tnc

1.12137 1.63376

Fgf5

1.70817 1.62636 2.21022 2.03669 2.83057 3.22394 3.57394

1.3383

1.17239 2.46639 2.56055 3.62416

Col4a4

1.18115 0.79161 1.24613 3.24429

Col2a1

1.26176 1.32693 1.07301 1.54373 2.37888 3.14634 3.48971

Fgf1

1.40207

Tnc

2.11921 2.68497 2.61349 3.31644

Pgf

1.09858 1.19162 1.28294 1.41341 2.43486

Bmp1
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Figure 17: Increase in expression of genes
associated with pre-metastatic niche in the fibrosis
environment. Probes fluorescent units are shown in
log scale. N=3 for each group.
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Figure 18: Fold Change expression for genes associated with the pre-metastatic niche and tumor
microenvironment in kidneys of indicated groups. The fold change in TGFB1, Fibronectin, Col1a1,
LOX, TNFa, FGF and VEGF in healthy kidneys, contralateral kidneys, fibrotic kidneys and the
kidneys of mice treated with bleomycin. Normalized to GAPHD. Data are represented as the mean
±SEM using One-Way Anova for *p < 0.05, **p < 0.01, ****p < 0.0001. ns, not significant.
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Chapter 4: The effect of organotropic and non-organotropic fibrosis on breast
cancer metastasis
To test the capacity of pro-tumorigenic fibrosis to enhance and/or reroute metastatic
disease we induced cutaneous skin wound, lung fibrosis, or kidney fibrosis in mice that
received 1) orthotropic 4T1 injections 2) intravenous 4T1 injections 3) or MMTV-Pymt tumor
bearing mice. By injecting 4T1 cancer cells orthotopically and utilizing the MMTV-Pymt
model we are able to model the spread of metastatic disease from the primary tumor
following the metastatic cascade. The use of the intravenous model allows us to remove
any influence from the primary tumor and to test the effects of fibrosis on both vasculature
and extravasation and on other host organs.
The effect of cutaneous skin wound on breast cancer metastasis
A long-standing concern within the surgical community has been the effect of
surgery on the spread of metastatic disease. Although there is limited evidence to show that
surgical wounds promote metastatic disease, and given that pro-tumorigenic factors from
wounds resolve after a few days we opted to determine whether induction of a cutaneous
wound could have any effects on the spread of metastatic disease. Mice where initially
injected bilaterally with 4T1 cancer cells into their mammary fat pads and monitored for
tumor growth. Once the 4T1 tumors had reached a combined growth of 500mm 3 the mice
where anesthetized and an 8mm dorsal non-peritoneal penetrating wound was surgically
induced. The same progression was used for the MMTV-Pymt with mice receiving a wound
once the combination of their tumors had reached a combined 500mm 3. Once the tumors
reached a combined 1500mm3 the mice were euthanized and tissues collected for analysis.
Additionally, we injected 4T1 cancer cells intravenously and induced wound on the same
day. Given the propensity for both these models to metastasize to the lungs we primarily
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focused our metastatic analysis on the pulmonary system. We also collected the kidneys
from all mice to analyze for potential metastatic spread and to compare to the other cohorts
with fibrotic lung and kidney.
To compare metastatic spread in mice with and without cutaneous wound we
performed H&E staining on the lungs and kidneys and counted metastasis microscopically.
As hypothesized, there was no significant difference between metastatic spread to the lungs
in the mice with and without cutaneous wound in either the 4T1 (Figure 19E, F, G) model or
the MMTV-Pymt model (Figure 19A, C, D). Similarly, we noted no difference in colonization
of the lungs in the intravenous 4T1 with or without cutaneous wound (Figure 19I, K, L).
There was no metastatic growth or colonization of the kidneys in any these mice (Figure
22A, B). There was no change in the growth rates of the tumors (Figure 19B, I).
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Figure 19: Metastatic Analysis in Cutaneous Wound A) Histological representation of MMTV-Pymt
metastasis with and without cutaneous wound. B) Pymt Tumor growth curve C) Metastatic and D) surface
lung nodule quantification of MMTV-Pymt mice with and without cutaneous wound. E) Histological
representation of 4T1 orthotopic metastasis with and without cutaneous wound. F) Metastatic, G) surface
lung nodule quantification and H) CTC analysis of 4T1 orthotopic mice with and without cutaneous wound.
I) Histological representation of 4T1 IV metastasis with and without cutaneous wound. J) 4T1 Orthotopic
growth curve K) Metastatic and L) surface lung nodule quantification of 4T1 IV mice with and without
cutaneous wound. N=6 for each group. Scale bar=25um. Data are represented as the mean ±SEM using
Student’s T-test for *p < 0.05, **p < 0.01, ****p < 0.0001. ns, not significant.
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The effects of lung fibrosis on breast cancer metastasis
Using the same methodology as in with the cutaneous wound we induced lung
fibrosis in 4T1 orthotopic, 4T1 intravenous, and MMTV-Pymt mouse models of breast
cancer either once the tumors had reached 500mm3 or on the same day as 4T1 intravenous
injection. These mice were euthanized 10 days post intratracheal Bleomycin lung fibrosis
inducing surgery. The 10 days euthanization was both for humane reasons and also due to
the rapid progression of metastatic disease in these mice. Analysis of these mice revealed
significant spread of 4T1 (Figure 20 E, F, G) and Pymt (Figure 20 A, C, D) metastasis and
colonization (Figure 20I, K, L) of the lungs in mice with lung fibrosis as compared to mice
that received only intratracheal PBS injections. None of these had metastasis to their
kidneys (Figure 22) or changes to their tumor growth (Figure 20B, J). The increased
metastasis and colonization of the fibrotic lungs in these mice indicates that the protumorigenic fibrotic environment is able to enhance metastatic spread to organotropic
organs. These results reflect previous publications and support the role of the
aforementioned pro-tumorigenic factors in promotion of metastasis.
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Figure 20: Metastatic Analysis in Lung Fibrosis A) Histological representation of MMTV-Pymt metastasis with
and without lung fibrosis. B) Pymt Tumor growth curve C) Metastatic and D) surface lung nodule quantification
of MMTV-Pymt mice with and without lung fibrosis. E) Histological representation of 4T1 orthotopic metastasis
with and without lung fibrosis. F) Metastatic, G) surface lung nodule quantification and H) CTC analysis of 4T1
orthotopic mice with and without lung fibrosis. I) Histological representation of 4T1 IV metastasis with and
without lung fibrosis. J) 4T1 Orthotopic growth curve K) Metastatic and L) surface lung nodule quantification of
4T1 IV mice with and without lung fibrosis. N=6 for each group. Scale bar=25um. Data are represented as the
mean ±SEM using Student’s T-test for *p < 0.05, **p < 0.01, ****p < 0.0001. ns, not significant.
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The effects of kidney fibrosis on breast cancer metastasis
To elucidate the ability of the pro-tumorigenic fibrotic environment to potentially
reroute metastasis to a non-organotropic organ we surgically induced kidney fibrosis
utilizing the same 4T1 and MMTV-Pymt methods and models and time course as the lung
fibrosis cohort. Given the presence of chronically and significantly upregulated expression
of pro-tumorigenic factors in the fibrotic kidney and publications reporting the chemotactic
properties of upregulating these factors on cancer cells we surmised that this environment
should reroute metastatic spread to the damaged kidney. Surprisingly, upon euthanization
of the mice with kidney fibrosis there was no macroscopically apparent metastatic nodules
in the 4T1 orthotopic, MMTV-Pymt of the 4T1 intravenous model (Figure 22A, B). Further
histological analysis of the kidneys confirmed the induction of fibrosis, and that despite the
development of this pro-tumorigenic environment, fibrosis was not able reroute metastatic
spread to a non-organotropic organ. This result indicates that while the previously reported
pro-tumorigenic factors found in the pre-metastatic niche are sufficient to enhance
metastasis to an already tropic organ, they are not sufficient to redirect metastatic spread.
The inability of the fibrotic environment to redirect metastatic disease indicates that there
are additional factors that affect metastatic tropism in addition to the previously reported
pre-metastatic niche alterations that occur in the tropic organs.
In addition to noting that fibrosis could not redirect metastatic disease to the nontropic kidney we also analyzed metastasis in the lungs of mice with kidney fibrosis.
Histopathological analysis revealed there was an increase in metastasis to the lungs of
mice that had kidney fibrosis. Increased lung metastasis was observed in the 4T1 orthotopic
model (Figure 21A, C, D) Similarly, metastasis to the lung was enhanced in the MMTVPymt model (Figure 21E, F, G) and also in the 4T1 intravenous model (Figure 21 I, K, L)
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Figure 21: Metastatic Analysis in Kidney Fibrosis A) Histological representation of MMTV-Pymt metastasis
with and without kidney fibrosis. B) Pymt Tumor growth curve C) Metastatic and D) surface lung nodule
quantification of MMTV-Pymt mice with and without kidney fibrosis. E) Histological representation of 4T1
orthotopic metastasis with and without kidney fibrosis. F) Metastatic, G) surface lung nodule quantification
and H) CTC analysis of 4T1 orthotopic mice with and without kidney fibrosis. I) Histological representation
of 4T1 IV metastasis with and without kidney fibrosis. J) 4T1 Orthotopic growth curve K) Metastatic and L)
surface lung nodule quantification of 4T1 IV mice with and without kidney fibrosis. N=6 for each group.
Scale bar=25um. Data are represented as the mean ±SEM using Student’s T-test for *p < 0.05, **p < 0.01,
****p < 0.0001. ns, not significant.
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Figure 22: Metastasis did not spread to the kidneys despite the fibrotic environment. A)
Representative images of kidneys from each cohort showing no metastatic growth. B) 4T1 GFP
labelled cells where visualized in the tumor and lung metastasis, but could not be located in the
kidneys of mice from any cohort. Scale bar=25um.
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Chapter 5: Kidney fibrosis increases the circulating levels of cytokines known
to affect vasculature
The finding that fibrosis cannot reroute metastatic disease, but can systemically
enhance the spread to tropic organs indicates that the fibrotic environment, similar in nature
to the primary tumor microenvironment releases factors that travel systemically and effect
various aspects of the host in an organ-specific manner. Given that in both the fibrotic lung
and fibrotic kidney there were significant increases in the presence of pro-tumorigenic
molecules in the stromal microenvironment we hypothesized that this organ-specific
reaction to circulating fibrotic cytokines might occur within a non-stromal aspect of the
organ.
Chronically elevated circulating cytokines during kidney fibrosis
To determine the cytokines elevated during fibrosis we initially performed an analysis
using Ilumina array data of fibrotic kidneys as compared to their healthy kidneys. Utilizing
genes that were increased in the fibrotic kidneys we performed pathway and gene ontogeny
analysis using the online software DAVID. Analysis of this data revealed significant changes
associated with both tight junctions and with vascular remodeling (Figure 23,24, 25).
Categorical analysis revealed a number of vascular related genes upregulated in the fibrotic
kidneys when compared to healthy kidneys. While these factors are associated with
alterations in tight junction structure and vasculature further experimentation was required
to determine which of the factors was also secreted into the circulation.
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Healthy Kidney

Fibrotic Kidney

Figure 23: Heat Map of genes differentially expressed in healthy
kidneys versus fibrotic kidneys. N=3 for each cohort.
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Figure 24: Gene Ontogeny and KEGG analysis from DAVID. A) The top 10 gene ontogeny terms of
upregulated genes in fibrotic kidneys as compared to healthy kidneys. B) The top 10 pathway terms
upregulated in fibrotic kidneys as compared to healthy kidneys.
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Based on the results of our gene array we selected a cytokine array from R&D
systems and ran multiple samples from healthy, cutaneous wound, fibrotic lung, and fibrotic
kidney serum. While a number of cytokines were increased in the serum of mice with
fibrosis as compared to the healthy and wounded serum, we noted that Angiopoietin 2 was
elevated both in our gene array data (Figure 25A) and in the serum of mice with kidney
fibrosis (Figure 25B, 26). To confirm our observations from the cytokine array we
performed an Angiopoietin 2 specific ELISA on the serum of all the cohorts and their
respective controls. In accordance with previously published data our basal levels of
Angiopoietin 2 were around 2000pg/ml. Most notably the serum Angiopoietin 2 levels of
mice with kidney fibrosis were significantly elevated (Figure 27). Interestingly, Angiopoietin
2 was not as elevated in the serum of mice with lung fibrosis as compared to the serum of
mice with healthy lungs (Figure 27). Furthermore, we also confirmed that in the fibrotic
kidney the gene expression of Angiopoietin 2 was increased (Figure 27).
These results suggest that fibrotic kidney damage releases continuous Angiopeotin2
into circulation at significantly elevated levels. Given that Angiopoietin 2 has been shown to
be an antagonist of Angiopoietin 1 and a destabilizer of endothelium cell-cell interactions
and tight junctions, we surmised that this could cause systemic alterations in vascular
permeability leading to increased likelihood of extravasation of circulating cancer cells.
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Figure 25: Vascular Adhesion Related Genes and Cytokine array in
multiple models of fibrosis. A) Genes associated adhesion and tight
junctions compared in healthy kidneys versus fibrotic kidneys. Probes
fluorescent units are shown in log scale. B) Heatmap of cytokines from
serum of healthy mice, mice with a cutaneous wound at day 10, mice
with lung fibrosis at day 10, and mice with kidney fibrosis at day 10. N=4
for healthy and wounded, and n=6 for fibrotic lung and fibrotic kidney.
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Figure 26: Quantitative Analysis of Serum Cytokine Array. The quantification of each cytokine in the
cytokine array. Data are represented as the mean ±SEM using One-Way Anova T-test for *p < 0.05,
**p < 0.01, ****p < 0.0001. ns, not significant.
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Figure 27: Increased serum and fibrotic kidney expression of Angiopoietin 2. A) Angiopoietin 2 ELISA
comparing healthy, wounded, PBS treated lung, Bleomycin fibrotic lung, contralateral kidney and UUO
induced fibrotic kidney serum for Angiopoietin 2. N=4 B) qPCR for Angiopoietin 2 expression in healthy
kidney, contralateral kidney, UUO induced fibrotic kidney, and kidney of mice with lung fibrosis. N=3 per
cohort. Data are represented as the mean ±SEM using Student’s T-test for *p < 0.05, **p < 0.01, ****p <
0.0001. ns, not significant.

Chapter 6: Circulating Angiopoietin -2 alters vasculature in organ specific
manner
The finding that fibrotic kidney increases circulating levels of Angiopoietin 2 led us to
look into how Angiopoietin 2 might influence organ vasculature in different manners and
whether this could have an effect on organotropism. This is of particular importance as
elevated levels of circulating Angiopoietin 2 have been linked with multiple pathologies
including diabetic retinopathy, pulmonary edema during sepsis, and a decrease in disease
free survival in breast cancer patients and thus a worse prognosis.
Given that the fibrotic kidney was found to have an upregulated expression of
Angiopoietin 2, but yet did not develop metastasis we hypothesized that the vascular
response to Angiopoietin 2 may be different in varying organs. Given the various forms and
functions of the mammalian organs it is reasonable that in addition to having physically
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different endothelium (continuous, fenestrated, and sinusoidal) each different organ may
respond to similar cytokines in different manners.
Differential Vascular permeability responses in the lungs and kidneys of mice treated
with Angiopoietin 2
In order to assess the vascular permeability in vivo we utilized FITC labelled dextran
(70,000kDa) injected into mice after two rounds of treatment with 100ug of Angiopoietin 2
intravenously. Control mice received PBS on the same day as the Angiopoietin 2 injections.
The lungs and kidneys were harvested from these mice and histological analysis was
performed on formalin fixed sections after antigen retrieval. By utilizing formalin fixed
sections, as opposed to frozen OCT we are able to get a significantly better visualization of
histological structure and thus a more precise analysis of location of FITC positivity. By
counterstaining with Isolectin B4 we can visualize vasculature and differentiate between
vascular spaces and parenchymal tissue. Analysis of the lungs of the mice treated with
Angiopoietin 2 clearly showed an increase in FITC positivity in parenchymal spaces (Figure
28A, B). In comparison the lungs of the mice treated with PBS showed specific localization
of FITC to within vessels in the lungs. These finding clearly indicate that elevated circulating
Angiopoietin 2 induced pulmonary vascular leakage.
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Figure 28: Increased dextran leakage in lungs of mice treated with
Angiopoietin 2. A) Representative immunofluorescent images of
the lungs of mice treated with PBS versus Angiopoietin 2 and
stained for Isolectin-B4. N=5 for each cohort. B) Quantification of
FITC positivity in perivascular parenchymal spaces in PBS versus
Angiopoietin 2 treated mice lungs. Scale bar=25um. Data are
represented as the mean ±SEM using Student’s T-test for *p <
0.05, **p < 0.01, ****p < 0.0001. ns, not significant.
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Utilizing the same methodology, we also analyzed the effect of Angiopoietin 2 on the
vasculature of the kidney. In stark contrast to the increased vascular leakage found in the
lungs of mice treated with Angiopoietin 2, there was no difference in FITC analyzed
vascular leakage of the kidney between the mice treated with Angiopoietin 2 compared to
the PBS treated mice. Given that the kidney consists of the cortex, outer medulla, and inner
medulla, all of which have different vascular physiology we analyzed all three areas for
potential vascular leakage. Yet, despite the highly vascular nature of the kidney we noted
no permeability difference between PBS and Angiopoietin 2 in the peritubular capillaries or
the vasa recta capillaries (Figure 29A, B). Given that the lungs and kidneys were harvested
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from the same mice we concluded that vascular endothelial response to circulating
cytokines such as Angiopoietin 2 is organ specific.
A

Figure 29: No dextran leakage in kidneys of mice treated with Angiopoietin 2. A) Quantification of
FITC positivity in perivascular parenchymal spaces in PBS versus Angiopoietin 2 treated mice
kidneys in the cortex, outer medulla and inner medulla. B) Representative immunofluorescent images
of kidneys of mice treated with PBS versus Angiopoietin 2 and stained for Isolectin-B4 in the kidney
cortex. C) Representative immunofluorescent images of kidneys of mice treated with PBS versus
Angiopoietin 2 and stained for Isolectin-B4 in the kidney outer medulla. D) Representative
immunofluorescent images of kidneys of mice treated with PBS versus Angiopoietin 2 and stained for
Isolectin-B4 in the kidney inner medulla. N=5 per cohort. Scale bar=25um. Data are represented as
the mean ±SEM using Student’s T-test for *p < 0.05, **p < 0.01, ****p < 0.0001. ns, not significant.

.
N=5 for each cohort.
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To analyze the pathological vascular effects of wounds, lung fibrosis and kidney
fibrosis on the lungs we performed histological analysis of the lungs from the mice with
wounds, fibrotic lung or fibrotic kidneys. Edema was measured by finding the area of
positive edema in both alveolar and pleural spaces. Pleural thickness was measured by
measuring the thickness of the lung pleura at 8 areas in each different lung. Our analysis
showed the lungs of mice with kidney fibrosis has significantly increased pulmonary edema
(Figure 30B, D) and pleural thickness (Figure 30A, C).
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Figure 30: Increased edema and lung damage in lung fibrosis and lungs of mice with kidney fibrosis. A)
Representative images of pleural thickness in the lungs of mice from each cohort. B) Representative images of
alveolar and pleural edema from the lungs of mice from each cohort. C) Quantification of pleural thickness from the
lungs of mice from each cohort. D) Quantification of alveolar and pleural edema from the lungs of mice from each
cohort. N=6 for Healthy, wound, PBS, Bleomycin, sham, and UUO. N=3 for Angiopeotin-2 cohort. Images taken at
63X. Data are represented as the mean ±SEM using Student’s T-test for *p < 0.05, **p < 0.01, ****p < 0.0001. ns,
not significant.
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Lung and kidney endothelial response to Angiopoietin 2 treatment in vitro
Using two in vitro endothelial cells lines isolated from the lungs and kidneys of an
SV-40 T-antigen mouse we tested the response to Angiopoietin 2 to determine if they had a
differential effect. While the predominance of previous studies used HUVECs to study
endothelial response in vitro, here we used endothelial cells isolated directly from the
organs of interest. HUVECs were isolated from umbilical cord cells which are not shown to
form metastatic disease, as compared to the lungs. This allowed us to compare the
response of lung and kidney endothelial cells when exposed to Angiopoietin 2. By treating
both cell lines with 1ug of Angiopoietin 2 we then immunofluorescently stained the cells for
Phalloidin and ZO-1. Although previous publications have shown response in HUVECs as
low as 400ng of Angiopoietin 2, we opted to use 1ug to ensure sufficient response of the
treated cell lines. The non-treated cell lines received PBS vehicle. ZO-1 costained with
Phalloidin permitted visualization of cellular borders and was additionally confirmed with
bright field imaging. The visualization of the cellular borders is necessary for ZO-1 analysis
as the tight junction complex is located between cells, with ZO-1 localizing to the cell
membrane to bind the transmembrane proteins that form the tight junction.
Analysis of ZO-1 localization in non-treated and treated lung endothelial cells clearly
indicated that after 30 minutes of Angiopoietin 2 treatment ZO-1 delocalized from the
endothelial cell membrane (Figure 31A, B). As ZO-1 is a critical protein in the formation of
the tight junction complex this indicates that lung endothelium become destabilized when
exposed to Angiopoietin 2.
Furthermore, by performing western blot analysis for phosphorylated Tie-2 Tyr1108
on cells treated with Angiopoietin 2 we clearly show that while the lung endothelial cells
react rapidly to the treatment, within 45 minutes to an hour they have returned to basal
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levels (Figure 31C). This fast reaction and return response indicates that once Angiopoietin
2 returns to basal levels in circulation the vasculature will rapidly stabilize. Conversely, with
chronically elevated circulating Angiopoietin 2 levels the vasculature will be unable to
stabilize and the lung endothelium will lose functioning tight junctions. The result of which
will be increased vascular permeability and increased potential for circulating tumor cells to
extravasate. Furthermore, there was a direct activation and increase in pERK which
coincided with the pTie2 in the lung endothelial cells treated with Angiopoietin 2 (Figure
31C).
Upon testing kidney endothelial cells, we found that their ZO-1 did not delocalize
from the membrane upon Angiopoietin 2 treatment (Figure 31D, E), although their levels of
pTie-2 responded rapidly within the first 5 minutes but decreased after that (Figure 31F).
Furthermore, the changes in pERK observed in the lung endothelial cells did not occur in
the kidney endothelial cells (Figure 31F). These results indicate that renal and lung
endothelial cells appear to react in a dissimilar manner when exposed to Angiopoietin 2.
Given that we reported that in vivo we observed no vascular leakage in the kidneys of mice
treated with Angiopoietin 2, this indicates that the vasculature responds in an organ-specific
manner.
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Figure 31: ZO-1 delocalized in lung endothelial cells, but not renal endothelial cells when treated with Angiopoietin
2 in vitro. A) Representative images of ZO-1 expression and membrane localization in lung endothelial cells treated
with PBS or Angiopoietin 2. B) Quantification of ZO-1 membrane localization in lung endothelial cells treated with
Angiopoietin 2. N=3 C) Western blot showing phosphoTie-2 Ty 1108, and p-ERK in lung and renal endothelial cells
treated with Angiopoietin 2 at 5, 15, 30, 45 and 60 minutes. Actin is the control. D) Representative images of ZO-1
expression and membrane localization in renal endothelial cells treated with PBS or Angioppoetin-2 E)
Quantification of ZO-1 membrane localization in renal endothelial cells treated with Angiopoietin 2. N=3 F) Western
blot showing phosphoTie-2 Ty 1108, and p-ERK in renal endothelial cells treated with Angiopoietin 2 at 5, 15, 30,
45 and 60 minutes. Scale bar=5um. Data are represented as the mean ±SEM using Student’s T-test for *p < 0.05,
**p < 0.01, ****p < 0.0001. ns, not significant.
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Organ specific tight junction response to Angiopoietin 2 treatment
As our in vitro results indicated that lung and kidney endothelial cells responded with
a dissimilar delocalization of ZO-1 upon Angiopoietin 2 treatment, we surmised that an
aspect of the vasculature must be responsible for organ-specific response to Angiopoietin 2
and the fibrotic environment. Given that capillaries are the predominant vascular structure
we hypothesized that pericytes and tight junctions may respond in differential manners
when endothelial cells are exposed to varying circulating cytokines. As capillaries do not
possess smooth muscle and have been shown to be regulated by pericyte activity we
choose to focus on the tight junction and pericyte response to fibrosis.
As fibrotic lungs enhanced metastasis, and fibrotic kidneys did not reroute
metastasis, but did enhance it to the lungs we compared gene expression by Illumina array
of healthy lungs versus healthy kidneys, healthy and fibrotic lungs, and healthy and fibrotic
kidneys. The purpose of these comparisons was to determine how tight junction and
pericyte gene expression response was differentially expressed in the healthy organs, and
how the response was different in the fibrotic lung versus the fibrotic kidney. We
hypothesized that gene signature differences in the fibrotic lung compared to the kidney
fibrosis may be responsible for the organ specific vascular response. We also analyzed the
gene expression level differences between healthy lungs and healthy kidneys to determine
if either organ was more dependent on a specific tight junction. As vascular permeability is
directly related the expression of tight junction proteins we analyzed the differential levels of
claudins, occuludin, the junction adhesion genes, the zonula occludin genes, and genes
known to be associated with pericytes.
The gene expression analysis revealed significantly different organ specific
responses to fibrotic insult within the fibrotic lung and kidneys. Analysis revealed that
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Claudin-5 expression decreased in the fibrotic lung, while it was increased in the fibrotic
kidney (Figure 32A, B, C). The importance of the differential changes in Claudin-5
expression were of particular interest given its role in the formation of tight junctions and
that is considered a key protein in endothelial tight junction barrier formation and modulation
of vessel permeability. Furthermore, we found that the expression of the Angiopoietin 2
receptor Tie 2 TEK gene expression in the healthy kidneys was significantly lower than in
the healthy lungs (Figure 32D), indicating that Angiopoietin 2 would affect endothelium at
different levels in the lung as compared to the kidneys. It is also possible that given the
chemotactic relationship between Tie 2 and Angiopoietin 2 that the circulating cytokine
moves more towards the lungs.
An analysis of the genes associated with pericytes noted no significant change in
desmin in the fibrotic lungs, but a significant increase in desmin in the fibrotic kidneys
(Figure 32A). Similarly, there was no significant change in PDGFRb in the fibrotic lungs, but
an increase in the fibrotic kidneys (Figure 32A). Finally, there was no significant change in
NG2 expression in either the fibrotic lung or the fibrotic kidneys (Figure 32A). Furthermore,
there was a significant decrease in the expression of Endothelin-1 in the fibrotic lungs while
the fibrotic kidneys showed a significant increase (Figure 32A). This is of interest given that
Endothelin-1 is synthesized and secreted by the endothelial cells and its known receptor is
expressed by pericytes. These differential responses indicate that the vasculature responds
differently in each organ and there is a thus a differential pericyte response.
These results indicate that pro-tumorigenic factors will illicit different responses in the
lung versus the kidney vasculature. The differential response functionally results in either
increased vascular permeability in the lung, or decreased vascular permeability in the
kidney. In the context of breast cancer, the increase in pulmonary vascular permeability
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enhances metastatic extravasation. Conversely a decrease in kidney vascular
permeabilization in the presence of pro-fibrotic factors prevents the extravasation of
circulating tumor cells and thus makes the kidney a rare organotropic organ in breast
cancer metastasis.
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Figure 32: Lung and kidney fibrosis show different expression of tight junction proteins. A) Heatmap of probes
for genes associated with tight junctions. Probes fluorescent units are shown in log scale. B) qPCR for Cldn-5
in a healthy versus a fibrotic kidney. N=3 C) qPCR for Cldn-5 in a healthy versus fibrotic lung. N=3. D) qPCR
for TEK with 2 different primers sequences N=3. Data are represented as the mean ±SEM using Student’s Ttest for *p < 0.05, **p < 0.01, ****p < 0.0001. ns, not significant.
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Chapter 7: Anti-Angiopoetion-2 rescues the metastatic enhancement effects of
kidney fibrosis
As we have identified Angiopoietin 2 as a factor secreted by the fibrotic kidney, and
as it has also been implicated in other vascular related pathologies we next wanted to
determine whether treatment of mice 1) with recombinant murine Angiopoietin 2 and
injected intravenously with 4T1 cancer cells or 2) with Angiopoietin 2 antibody peptide that
had both kidney fibrosis and breast cancer could rescue the enhanced metastatic
phenotype. Mice injected with recombinant murine Angiopoietin 2 one day prior and oneday post intravenous injection with 4T1 cancer cells (Figure 33A) showed significant
increase in colonization of the lungs (Figure 33B, C, D). We then utilized the orthotopic
model either given control IgG or treated with the Angiopoietin 2 peptide. Mice treated with
IgG had either no kidney fibrosis or kidney fibrosis, and similarly mice treated with the
Angiopoietin 2 peptide had either kidney fibrosis or no kidney fibrosis. In the mice the
control group treated with IgG we saw an increase in metastasis to the lungs similar to the
previous phenotype in Figure 21 (Figure 33F, G, H). When the mice where treated with the
Angiopoietin 2 peptide we saw the metastatic burden in the lungs of mice kidney fibrosis
return similar levels of mice without kidney fibrosis (Figure 33F, I, H). These results indicate
that Angiopoietin 2 was a key factor in the enhancement of metastatic spread and
colonization of lungs in mice with kidney fibrosis.
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Figure 33: Anti-Angiopoetin 2 Antibody in Tumor Bearing mice with Kidney Fibrosis Reduces Lung Metastasis to
Levels of Mice without Kidney Fibrosis. A) Schematic of time course treatment with recombinant murine
Angiopoietin 2 and injected intravenously with 4T1 cancer cells. B) Quantification of colonization of the lungs of
mice treated with PBS or recombinant murine Angiopoietin 2 and injected intravenously with 4T1 cancer cells. N=6.
C) Quantification of surface lung nodules of mice treated with PBS or recombinant murine Angiopoietin 2 injected
intravenously with 4T1 cancer cells. N=6. D) Representative images of the lungs of mice treated with either PBS or
recombinant murine Angiopoietin 2 and injected intravenously with 4T1 cancer cells. Scale bar=25 um. E) Tumor
volume measurements over time in orthotopic tumors with sham or UUO and either treated with IgG or antiAngiopoietin 2. Two-way Anova with Tukey’s multiple comparison test was used. F) Quantification of the metastatic
area of the lungs of the indicated groups. N=8 per group. One-Way Anova was used. G) Representative images of
lungs of mice with either sham or UUO treated with IgG. Scale bar=25 um. H) Quantification of the number of
surface lung nodules in the indicated groups treated with IgG. N=8 per group. I) Representative images of lungs of
mice with either sham or UUO treated with anti-Angiopoietin 2. Scale bar=25 um. J) Quantification of the number of
surface lung nodules in the indicated groups treated with anti-Angiopoietin 2. N=8 per group. Data are represented
as the mean ±SEM using Student’s T-test unless otherwise noted. *p < 0.05, **p < 0.01, ****p < 0.0001. ns, not
significant.
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Summary of Results
Herein we set out to determine the role of the fibrotic environment in the
determination of breast cancer metastatic organotropism. By showing the significant
similarities between the fibrotic lung and kidney for factors previously associated with the
pre-metastatic niche and organotropism we developed a way to test the contribution of
these factors on metastatic tropism. As expected the fibrotic environment in a tropic organ
enhanced metastasis to that organ. However, despite previous evidence implicating the
growth factors in the control of metastatic spread we did not see any metastasis to the
fibrotic kidney. None the less the fibrotic kidney did enhance metastatic spread to the lungs.
This led us to hypothesize that there was an alternative organ specific alteration that
occurred due to the secretion of pro-tumorigenic fibrotic factors into circulation. We
identified Angiopoietin 2 as a cytokine that is found to be upregulated in the circulation of
fibrotic kidney disease. Previous research has also shown that Angiopoietin 2 is
upregulated in patients with breast cancer and is prognostic of decreased disease free
survival. By treating mice with Angiopoietin 2 we observed an organ specific vascular
response leading to increased vessel permeability in the lungs, and a converse reaction in
the kidneys. Further analysis revealed that there is an organ specific vascular response
mediated by the expression of the tight junction protein Claudin-5. Finally, by treating tumor
bearing mice that had fibrotic kidney damage with recombinant murine Angiopoietin 2 we
showed that the enhanced metastatic phenotype could be enhanced, and it could be
rescued by treating tumor bearing mice with kidney damage with anti-Angiopoietin 2.
Together, our results show for the first time that organotropism is due to an organ specific
vascular response to increased levels of circulating cytokines.
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Chapter 8: Summary and Discussion
The recognition that primary tumors have specific tropism for metastatic spread has long
been an area of research (Fidler 2003) in the hopes of determining the mechanisms that
control metastasis. The ultimate goal being the development of therapies aimed at treating
and preventing metastasis. Given the fact that modern therapies are all but unable to treat
metastatic disease and the poor prognosis associated with the diagnosis, this continues to
be a high priority in cancer research. Since Virchow, Paget and Ewing (Talmadge and Fidler
2010) first began the study of metastatic disease the predominant focus of research has
been to ask why cancer has tropism for specific organs. Given the failure of this approach to
determine the mechanistic control of organotropism we choose to approach this issue from
an alternative viewpoint. In this study we focused on not only asking why cancer spreads to
the tropic organ, but also why it does not spread to non-organotropic organs. By developing
a pro-tumorigenic environment in both a tropic and non-organotropic organ for two
commonly used breast cancer metastasis models, we were able to elucidate the
contribution that this environment plays in directing metastatic spread. This also allowed us
to identify that an organ-specific vascular response to increased pro-tumorigenic cytokines
may in fact be a key determining mechanism in organotropism of metastatic disease.
Although it is considered common medical knowledge that organs have different structural
vascular mechanics (Junqier Histology), the finding that organ-specific vasculature
responds differently to the same cytokines, is a novel finding and may pave the way for the
research and development of organ-specific therapies not only for cancer related diagnosis
but also for organ specific pathologies.
The Unusual Suspects; Organotropism is not determined by previously published
factors complicit in the pre-metastatic niche
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While it has commonly been published that the tumor microenvironment, the pre-metastatic
niche and the fibrotic environment are considered similar (Arwert, Hoste and Watt 2012),
the ability of this environment to direct metastasis has not been truly tested. If these
environments are all biochemically and biophysically similar, then the induction of fibrosis
should enhance metastatic spread regardless of the organ of damage. Although some
research has been done to show that the fibrotic environment can enhance metastasis
(Erlner 2016), this has only been done in organs that are already tropic for that primary
tumor. While this is relevant research, it does not fundamentally test the ability of the known
pro-tumorigenic fibrotic factors to actually direct metastasis. If the fibrotic factors are the
determinants of organotropism then regardless of location, when significantly upregulated,
metastasis should spread to that organ. However, we clearly show here that that is not the
case. This finding indicates that while these pro-tumorigenic fibrotic factors are able to
enhance metastasis they are insufficient in directing organotropism. This indicates that
alternative factors are the source of the mechanism of organotropism. While our model of
surgically induced kidney fibrosis and chemically induced lung fibrosis do show increases in
fibrotic factors it is important to note that the induction methods may elicit different fibrotic
development. The surgically induced fibrosis causes an increase in shear stress in the
proximal tubules due to an increase in pressure from un-excreted filtrate. This increase in
continued shear stresses leads to proximal tubule damage and the chronic release of
fibrotic factors ultimately leading to kidney fibrosis. While the chemical induction in the lungs
is a response to the DNA damage agent bleomycin leading to an increase in epithelial cells
releasing pro-fibrotic factors. It is possible that the different methods of induction elicit
different responses. Nonetheless, we clearly show that the factors implicitly believed to be
the controlling factors for organotropism are upregulated in both our lung and kidney fibrosis
models. Given that the kidney fibrotic environment could not re-route metastasis we
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concluded that alternative factors must be responsible for the control of organotropism. This
result would indicate a paradigm shift as it clearly indicates that the pre-metastatic niche,
that is significantly similar to the fibrotic environment is not sufficient to direct metastatic
spread. While this indicates that the fibrotic factors are not responsible for directing
organotropism, it does not mean that they are not responsible for the enhancement of
metastasis. In fact, our findings profoundly support previous studies showing that these
factors are pro-tumorigenic for metastatic enhancement.

The seed grows where you want, you just have to put it there.
In addition to the pre-metastatic niche being implicated in the determination of
organotropism, the currently held belief for organotropism is that disseminated cancer cells
only grow in specific organs based on Paget’s seed and soil hypothesis. However, previous
publications have shown that murine cancer cell lines that are known to be organotropic for
specific organs can grow in non-organotropic organs. The key example of this would be the
growth of 4T1 or B16-F1 cells in the kidneys of mice injected under hydrostatic pressure (Li
and Liu 2011), and 4T1 cells directly injected into either the renal capsule or the cortex
(Daniel Guimarães Tiezzi 2013). In these experiments a mammary fat pad cancer cell line
that does not typically metastasize or colonize the kidney successfully grew in the kidneys.
Physiologically, the only key system that is bypassed by these experiments is the vascular
system. In the hydrostatic model they cause systemic vascular permeabilization by
mechanistically overloading the osmotic pressure within the vessels. The direct injection
models bypass the vascular system by simply being directed into the parenchymal
perivascular spaces. Regardless of the method, the important point here is that these cell
lines successfully grew in the kidneys when the vascular system is not an obstacle. By the
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process of elimination, it is clear that the vasculature is an essential barrier to metastatic
growth. However, the endothelial layer is a barrier to extravasation systemically, not just in
the kidneys. In the lungs circulating cancer cells must also extravasate. Yet, under
conditions where the primary tumor is grown orthotopically or injected intravenously under
normal hemostatic pressures these cancer cells only grow in the lungs and other tropic
organs. This indicates that the vasculature of different organs may behave differently
depending on the organ. Observations supporting this is that lung fibrosis and kidney
fibrosis release different levels of circulating Angiopoietin-2. While previous studies have
shown that there is less Angiopoietin-2 expressed in the lungs as compared to the kidneys
at basal non-pathological levels (Gale and Yancopoulos 2002), our results indicate that this
is also true in the pathological state as well. Additionally, our Illumina array study comparing
fibrotic lungs to healthy lungs showed that Angiopoietin 2 expression decreased significantly
in the fibrotic lungs. There are many possible reasons for this and they are most likely
related to the specific functions of the two organs. The lungs most likely have lower basal
levels of Angiopoietin 2 as increased pulmonary vascular permeability would not be
conducive to the organism as a whole and is generally restricted to tip cells in the lungs
(Feltch 2012). Conversely, changes in vascular permeability in the kidneys under the control
of Angiopoietin 2 might be useful for angiogenesis and also for the increased permeability of
molecules required for reabsorption into circulation. Interestingly, a recent paper studying
cerebral cavernous malformations found that increased levels of Angiopoietin 2 show a
decrease in Claudin 5 expression in the brain (Zhou 2016). Given that breast cancer is
known to metastasize to the brain, this indicates that Angiopoietin 2 has a similar vascular
permeability mechanistic effect on both the lungs and brain lending further evidence to the
organ specific responses to Angiopoietin 2. This further evidences a differential response to
the same cytokine under similar pathological conditions. We induced fibrosis in both lung
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and kidneys, and yet the lungs showed a different vascular response than did the kidneys,
despite the fact that pro-tumorigenic factors where increased in both organs.
The organ-specific vascular response was further evidenced by the differences in vessel
permeability as observed when mice where treated with Angiopoietin 2 and FITC-Dextran
and the response of the organ-specific cell lines. Similar to publications showing that
increased circulating Angiopoietin 2 induces pulmonary edema and increased lung vascular
permeability (Parikh and Sukhatme 2006) we also noted the same, but no such change in
the kidney. This was mirrored in the in vitro studies. When taken together with the evidence
that increased expression of Angiopoietin 2 is correlated with a poor disease-free prognosis
in breast cancer patients, this indicates that the fibrotic cytokine Angiopoietin 2 specifically
causes vessel leakage in the lungs, but not in the kidneys.
While Angiopoietin 2 is only one of many pro-tumorigenic cytokines released into circulation
it is the observation that it elicits an organ-specific response that is most important. The next
step in this area of research would be to test the vascular effects of injecting mice with protumorigenic factors such as TGFb, TNFa etc. Given that many of these cytokines are
upregulated in the circulation of patients with tumors, it may be that the organ vascular
response is what determines organotropism by vessel permeability. Taken a step further it
may also be that the endothelial vessel response is specific in other mechanistic properties
as well. For example, the expression of ICAM1 and VCAM1 by endothelial cells induced by
the increased presence of pro-tumorigenic factors in circulation is a key mechanism for the
binding of lymphocytes to endothelial cells for diapedesis. Given that we show that
endothelial cells can respond differently, it is plausible that different organ endothelial cells
may express different membrane receptors when exposed to pro-tumorigenic cytokines that
better enable the binding of circulating tumor cells to the endothelial lumen and increase
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their ability to cross into the perivascular space (Nolan 2013). Our finding also highlights the
need to determine the specific cytokines that are released by differing primary tumors. If all
primary tumors released the same cytokine profile, then one would surmise, based on our
findings, that they would all have similar organotropism. However, it is known that that is not
the case (Drandoff 2004). Therefore, we would surmise that different primary tumors, and
possibly even tumors with different genetic mutations would have a different circulating
cytokine profile. This differing circulating cytokine profile may therefore affect only some
organs in a manner that makes them more susceptible to metastatic spread.

It is all tight junctions all the time
An area of study that is woefully under researched is the tight junctions that exist between
endothelial cells. To date only Claudin-5 has been identified as a tight junction claudin
involved in endothelial cells. The remaining proteins involved in the tight junctions of the
endothelial cells have not been pursued in depth. Given that tight junctions are a key
complex in the formation of the vascular barrier and cell-cell contacts, this is an area that
requires more focus. Furthermore, similar to the claudin heterogeneity found in epithelial
cells, this is likely an organ-specific difference that will be key in determining organ
responses to circulating cytokines in both normal and pathological states (Nolan 2013).
Given the endothelial mouse models that exist today, this area of research is more
accessible than it was previously. The development of Tie-1, Tie-2, and CDH5 Cre mice
tagged with a fluorescent promoter would allow the visualization and or Fluorescent
Activated Cell Sorting sorting of these cells from specific organs to determine by both qPCR
and protein staining the expression of the different proteins involved in tight junction
complex formation (Nolan 2013). While we identified an organ-specific response for the
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endothelial Claudin-5 tight junction complex, it is unlikely that this is the only claudin, or JAM
implicate in the formation of endothelial tight junctions. Identification of the proteins that are
differently required in each organ will open the door for possible organ-specific therapies. A
good example of this would be with the blood-brain barrier. The main issue behind treating
cerebral pathologies is that the blood-brain barrier is often impenetrable by drugs injected
intravenously. The determination of the specific tight junction proteins involved in this barrier
may allow for the momentary increase in cerebral vessel permeability with co-treatment of
drugs typically unable to cross the blood-brain barrier. This will also allow for the
development of new therapies and determination of adverse effects. For example, in the
mice we treated with anti-Angiopoietin 2 we noted that there was a decrease in metastatic
lung disease. Given our research into the kidney we could hypothesize that there would be
limited to no negative renal effects. Given that currently there are trials for anti-Angiopoietin
2 therapy for cancer patients, this is an important finding.
In addition to cancer, this also holds vital findings for other systemic pathologies. As
previously mentioned, patients with sepsis are commonly affected by pulmonary issues,
including but not limited to pulmonary edema. Basic science research has linked this to
excess Angiopoietin 2 in circulation. Furthermore, a less well studied pathology known as
uremic lung also results in both alveolar and pleural pulmonary edema. Uremic lung occurs
in patients who have either acute or chronic renal damage. It was noted that in the 1940s,
during World War II, patients with kidney damage often required ventilators due to breathing
issues. This was originally believed to be related to hypervolemia, and thought to resolve
with the advent of dialysis. However, this was not the case and uremic lung still possess an
issue for patients with renal damage today. In both these cases, the excess of circulating
Angiopoietin 2 occurred in an unrelated organ and yet significantly adversely affected the
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lungs. By focusing research on which cytokines affect which organs in what specific
manners we can begin to develop focused therapies to combat organ specific disease.

Multiple factors affecting organotropism
While our research has shown that the previous factors implicated in the pre-metastatic
niche and fibrotic environment are able to enhance metastasis, they are not able to direct
organotropism as previously believed. Furthermore, we implicate the vasculature in
organotropism and show that organ-specific vascular responses to circulating cytokines
may illicit organ-specific responses. Our research, taken in the context of previous
publications, indicates that metastatic organotropism is likely a process that is based on the
following three fundamental factors:
1) Primary tumor releases multiple subpopulations of circulating tumors cells that
have differing ability to cross organ-specific endothelial barriers.
2) Primary tumor releases specific cytokine signature that systemically travel
through circulation but affect different organ vasculature in different manners
causing organ-specific alterations in endothelial behavior making specific organs
susceptible to metastasis.
3) Tumor secreted cytokines affect different organ environments in different
manners enhancing metastatic potential.
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